Poster Presentations

CARDIOVASCULAR DISORDERSClinical Outcomes Studies

PCV1	THE ROLE OF LDL-LEVELS IN INITIATING STATIN TREATMENT
	van der Bij S¹, Heintjes E¹, Plat A¹, Sturkenboom MC², Penning-van Beest FJ¹, Herings RMC¹
	¹PHARMO Institute, Utrecht, Netherlands, ²Erasmus University Medical Center, Rotterdam, Netherlands

PCV2	UNDERUSE OF STATINES AMONG HIGH RISK PATIENTS
	Heintjes EM¹, Haak P¹, Sturkenboom MC², Penning-van Beest FJA¹, Herings R¹
	¹PHARMO Institute, Utrecht, Netherlands, ²Erasmus University Medical Center, Rotterdam, Netherlands

PCV3	COMPARISON OF GOAL ATTAINMENT RATES BETWEEN USERS OF SIMVASTATIN 40 MG AND OTHER STATINS
	Heintjes E¹, Plat A¹, Sturkenboom MC², Penning-van Beest FJ¹, Herings RMC¹
	¹PHARMO Institute, Utrecht, Netherlands, ²Erasmus University Medical Center, Rotterdam, Netherlands

PCV4	COMPARISON OF THE CLINICAL AND ECONOMIC EFFECTIVENESS OF SIROLIMUS-ELUTING VERSUS BARE-METAL STENTS IN A SUBGROUP OF PATIENTS WITH AND WITHOUT DIABETES
	Brüggenjürgen B, McBride D, Roll S, Willich SN
	Charité University Medical Center, Berlin, Germany

PCV5	A REAL WORLD COMPARISON OF COMBINED LIPID TARGET ATTAINMENT BETWEEN COMBINATION NIACIN EXTENDED-RELEASE+ANY STATIN THERAPY AND FIXED DOSE SIMVASTATIN+EZETIMIBE
	Simko RJ¹, Quimbo RA², Cziraky MJ³, Balu S⁴
	¹Abbott Laboratories, Abbott Park, IL, USA, ²HealthCore Inc, Wilmington, DE, USA, ³HealthCore, Inc, Wilmington, DE, USA, ⁴Abbott Labs, Abbott Park, IL, USA

PCV6	EFFECTIVENESS OF CLOPIDOGREL IN ADDITION TO ASPIRIN COMPARED TO ASPIRIN ALONE AFTER ACUTE CORONARY SYNDROME
	Liew D¹, Price N², Chew DP³
	¹The University of Melbourne, Melbourne, Australia, ²Sanofi-aventis Australia, Sydney, Australia, ³Flinders University, Bedford Park, SA, Australia

PCV7	CLINICAL EFFECTIVENESS OF BOSENTAN, EPOPROSTENOL, ILOPROST, SILDENAFIL AND TREPROSTINIL IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION – A SYSTEMATIC REVIEW
	Becla L, Osińska B, Malottki K, Lipska I
	Agency for Health Technology Assessment, Warszawa, Poland

PCV8	CLINICAL AND ECONOMIC IMPACT OF DRUG-ELUTING STENT AND BARE METAL STENT IN HONG KONG– A SINGLE CENTRE “REAL WORLD” EXPERIENCE
	Lee VWY, Kum L, Lee T, Wong W, Chan C, Mak C, Lee KK, Yu CM
	The Chinese University of Hong Kong, Shatin, Hong Kong

PCV9	AN ANALYSIS OF THE ANTIHYPERTENSIVE EFFECTIVENESS OF IRBESARTAN VS. CANDESARTAN
	Sharplin P¹, Beckham C², Hogan S³, Chamberlain G¹
	¹CRC, Cardiff, United Kingdom, ²Bristol-Myers Squibb, Uxbridge, United Kingdom, ³Sanofi-Aventis, Guildford, United Kingdom

PCV10	SUPERIOR FORGIVENESS WITH ALISKIREN IN THE PRESENCE OF IMPERFECT COMPLIANCE
	Jung W¹, Tousset E², Lowy A³, Keefe D⁴, Vrijens B⁵, Vincze G³
	¹Academic Hospital Villingen, Villingen-Schwenningen, Germany, ²Pharmionic Systems, Vise, Belgium, ³Novartis Pharma AG, Basel, Switzerland, 4Novartis Pharmaceuticals Corp, East Hanover, NJ, USA, 5Pharmionic Systems, Visé, Belgium

PCV11	EFFECTIVENESS OF DRUG-ELUTING STENTS VS. BARE METAL STENTS UNRESTRICTED USE IN PATIENTS WITH CORONARY HEART DISEASE IN SOCIAL SECURITY MEXICAN INSTITUTE
	González-Díaz B¹, Contreras-Hernandez I¹, Castaño-Guerra R², Farell-Campa J², Arguero-Sànchez R², Morales-Cisneros G¹, Estrada-Gallegos J¹, Garduño-Espinosa J¹
	¹Social Security Mexican Institute, Mexico City, Mexico, ²Hospital de Cardiologia Centro Medico Nacional Siglo XXI, Mexico City, Mexico

PCV12	AN ANALYSIS OF THE ANTIHYPERTENSIVE EFFECTIVENESS OF ARBS VS. ACE INHIBITORS
	Sharplin P¹, Televantou F², Beckham C³, Chamberlain G¹
	¹CRC, Cardiff, United Kingdom, ²Sanofi-Aventis, Guildford, United Kingdom, ³Bristol-Myers Squibb, Uxbridge, United Kingdom

PCV13	ATTAINMENT OF MULTIPLE RECOMMENDED LIPID LEVELS FOLLOWING LIPID MODIFYING TREATMENT IN HIGH RISK PATIENTS. PRIMULA STUDY, SPAIN
	Suarez C¹, Maiques A², Ambegaonkar B³, Melero M⁴, Nocea G⁵, Zhang Q³, Sazonov V³
	¹H. de La Princesa, Madrid, Spain, ²Centro de Salud de Manises, Valencia, Spain, ³Merck & Co., Inc, Whitehouse Station, NJ, USA, ⁴Merck Sharp & Dohme, Madrid, Spain, ⁵MSD Spain, Madrid, Spain

PCV14	CENTRALISED PAN-EUROPEAN SURVEY ON THE UNDER-TREATMENT OF HYPERCHOLESTEROLEMIA IN PATIENTS USING LIPID LOWERING DRUGS (CEPHEUS-GREECE)
	Elisaf M¹, Daskos G², Nikas N²
	¹University Hospital of Ioannina, Ioannina, Greece, ²AstraZeneca SA, Athens, Greece

PCV15	CORONS STUDY: EXAMPLE OF STATINS IMPACT ON ALL CAUSE MORTALITY IN THE ELDERLY
	Kieffer A¹, Turbelin C¹, Rabeharimanana F¹, Flahault A²
	¹INSERM, Paris, France, ²EHESP, Paris, France

PCV16	MONITORING POTENTIAL DRUG-DRUG INTERACTIONS – AN APPLICATION FOR PRESCRIPTION CLAIMS DATABASES
	PCV98 ¹, Chang S², Misra A², Hansen LG³
	¹Thomson Reuters, Philadelphia, PA, USA, ²Thomson Reuters, Washington, DC, USA, ³Thomson Reuters, Northwood, NH, USA

PCV17	COLD AND INACTIVITY: THE ULTIMATE FACTORS FOR HEART ATTACK
	Horváth L¹, Vadász R¹, Bódis J¹, Boncz I¹, Sebestyen A², Temesvári B¹, Koppán Á¹, Kriszbacher I¹
	¹University of Pecs, Pecs, Hungary, ²National Health Insurance Fund Administration, Pecs, Hungary

PCV18	EFFECT OF ENVIRONMENTAL TEMPERATURE AND WORKDAYS ON HEART ATTACK FIGURES
	Vadász R¹, Bódis J¹, Boncz I¹, Sebestyen A², Temesvári B¹, Horváth L¹, Koppán Á¹, Kriszbacher I¹
	¹University of Pecs, Pecs, Hungary, ²National Health Insurance Fund Administration, Pecs, Hungary

PCV19	THE TIME OF SUNRISE AND HOURS WITH DAYLIGHT MAY HAVE AN EFFECT ON THE SEASONALITY AND DIURNAL VARIATION OF A HEART ATTACK
	Kriszbacher I¹, Bódis J¹, Sebestyen A², Koppán Á¹, Boncz I¹
	¹University of Pecs, Pecs, Hungary, ²National Health Insurance Fund Administration, Pecs, Hungary

PCV20	PREDICTED CARDIOVASCULAR EVENT REDUCTION WITH THE CO-ADMINISTRATION OF FENOFIBRIC ACID AND STATINS IN A DYSLIPIDEMIA PATIENT COHORT
	Sorensen SV¹, Webb SF², Burge RT²
	¹United BioSource Corporation, Bethesda, MD, USA, ¹Abbott Laboratories, Abbott Park, IL, USA

PCV21	EFFECT OF WEATHER CONDITIONS ON THE MORTALITY OF HEART ATTACKS IN HUNGARY
	Kriszbacher I¹, Boncz I¹, Sebestyen A², Vas G¹, Bódis J¹
	¹University of Pecs, Pecs, Hungary, ²National Health Insurance Fund Administration, Pecs, Hungary

PCV22	TOLERABILITY OF ROSUVASTATIN 40MG COMPARED TO 20MG IN THE TREATMENT OF HYPERCHOLESTEROLAEMIA: EVIDENCE FROM RANDOMISED CONTROLLED TRIALS
	Edwards SJ, Kingslake SL
	AstraZeneca UK Ltd, Luton, United Kingdom

PCV23	WITHDRAWN

CARDIOVASCULAR DISORDERSCost Studies

PCV24	BUDGET IMPACT OF GUIDELINE ADHERENT THERAPY IN ACUTE CORONARY SYNDROME (ACS) IN GERMANY
	Neubauer AS¹, Zeymer U², Blankenfeld H³, Marschall D¹, Ehlken B³, Plesnila-Frank C³, Berger K³
	1Bristol-Myers Squibb, Munich, Germany, 2Herzzentrum Ludwigshafen, Ludwigshafen, Germany, 3IMS Health, Munich, Germany

PCV25	BUDGET IMPACT ANALYSIS OF THROMBOLYSIS FOR STROKE: A DISCRETE EVENT SIMULATION MODEL
	Mar J¹, Arrospide A², Comas M³
	¹Hospital 'Alto Deba', Mondragon, Spain, ²Hospital Alto Deba, Mondragon, Spain, ⁴Hospital del Mar (IMAS), Barcelona, Spain

PCV26	TREATING TO LOWER LDL-C TARGETS: ESTIMATING THE NUMBER AND COST OF CARDIOVASCULAR EVENTS AVOIDED FOR REGIONAL HEALTH ECONOMIES IN ENGLAND, SCOTLAND, WALES AND NORTHERN IRELAND
	Kingslake SL
	AstraZeneca UK Ltd, Luton, United Kingdom

PCV27	MODELING THE FISCAL IMPACT OF USING PERFLUTREN LIPID MICROSPHERES (PLM) FOR FOLLOW-UP ECHOCARDIOGRAPHIC IMAGING
	Miller JD¹, Denevich S¹, McGarry MJ², Albano MP², Caloyeras JP¹, Russell MW¹
	¹Abt Bio-Pharma Solutions, Inc, Lexington, MA, USA, ²Lantheus Medical Imaging, Inc, North Billerica, MA, USA

PCV28	WITHDRAWN



PCV29	ESTIMATING THE BUDGET IMPACT OF DABIGATRAN ETEXILATE IN THE PRIMARY PREVENTION OF VENOUS THROMBOEMBOLISM FOLLOWING TOTAL HIP OR KNEE REPLACEMENT SURGERY: AN INTERACTIVE MODEL FOR LOCAL HEALTH ECONOMIES IN THE UK
	Robinson P¹, Zah V²
	1Boehringer Ingelheim Ltd, Bracknell, United Kingdom, 2ZRx Outcomes Research Inc, Toronto, ON, Canada

PCV30	COST-EFFECTIVENESS ANALYSIS OF ENDOVASCULAR ANEURYSM REPAIR (EVAR) FOR ABDOMINAL AORTIC ANEURYSM (AAA) IN SPAIN
	Rodriguez Barrios JM¹, Cairols M², Brosa M³, Crespo C⁴, Brasseur P⁵
	¹Medtronic Iberia, Madrid, Spain, ²Bellvitge Hospital, Barcelona, Spain, ³Oblikue Consulting, Barcelona, Spain, ⁴Barcelona University, Barcelona, Spain, ⁵Medtronic Sarl, Tolochenaz, Switzerland

PCV31	ORAL ANTICOAGULATION AFTER MAJOR HIP OR KNEE REPLACEMENT SURGERIES
	Wilke T
	University of Wismar, Wismar, Germany

PCV32	ECONOMIC EVALUATION OF ATORVASTATIN AND ROSUVASTATIN USING HEAD-TO-HEAD RANDOMIZED CONTROLLED TRIAL WITH UP-TITRATION OF DRUG DOSES TO OBTAIN THERAPEUTIC TARGETS FOR LDL-CHOLESTEROL
	Beamer B1, Frial T¹, Farahani P²
	1AstraZeneca Canada, Mississauga, ON, Canada, 2McMaster University, Hamilton, ON, Canada

PCV33	COST OF OUTPATIENT HYPERTENSION PHARMACOTHERAPY - COMPARATIVE STUDY BETWEEN BULGARIA AND SERBIA
	Ivanova AD¹, Lakic D², Andric V³, Petrova GI¹
	¹Medical University, Faculty of Pharmacy, Sofia, Bulgaria, ²Belgrade University, Faculty of Pharmacy, Belgrade, Serbia and Montenegro, ³Republic Institute for Health Insurance, Belgrade, Serbia and Montenegro

PCV34	COST-EFFECTIVENESS OF GADOFOSVESET-ENHANCED MAGNETIC RESONANCE (MR) ANGIOGRAPHY FOR THE PATIENTS WITH CHRONIC PERIPHERAL ARTERIAL OBSTRUCTIVE DISEASE (PAOD) IN KOREA
	Choi SE, Choi YG, Lim EA
	Seoul National University, Seoul, South Korea

PCV35	COST-EFFECTIVENESS ANALYSIS OF STROKE REHABILITATION STRATEGIES IN EASTERN CHINA
	O'Prinsen AC¹, Redekop WK²
	¹Philips Research Asia, Shanghai, China, ²Erasmus Medical Center, Rotterdam, Netherlands

PCV36	COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF TRITACE COMB (RAMIPRIL/HCTZ) IN TREATMENT OF HYPERTENSION IN POLAND
	Kawalec P¹, Lis J², Glasek M²
	¹Centrum HTA, Krakow, Poland, ²Sanofi-Aventis sp. z o.o, Warsaw, Poland

PCV37	ENOXAPARIN IS COST-SAVING AS PROPHYLACTIC THERAPY VERSUS UNFRACTIONATED HEPARIN OR NO PROPHYLAXIS IN HOSPITALISED MEDICAL PATIENTS
	Feng J¹, Yuen C², Jackson D³
	¹IMS Health Australia, St Leonards, Australia, ²Sanofi-Aventis Australia, Macquarie Park, Australia, ³IMS Health Australia, St leonards, Australia

PCV38	EXTENDED PROPHYLAXIS OF VENOUS THROMBOEMBOLISM (VTE) IN PATIENTS UNDERGOING MAJOR ORTHOPAEDIC SURGERY IN ITALY: A PHARMACOECONOMIC STUDY
	Capri S¹, Ageno W², Moia M³, Imberti D⁴, Palareti G⁵, Piovella F⁶, Scannapieco G⁷, Bamfi F⁸, Pitrelli A⁸
	¹Cattaneo-LIUC University, Castellanza, (Varese), Italy, ²University of Insubria, Varese, Italy, ³Fondazione IRCCS Ospedale Maggiore Policlinico, Milano, Italy, ⁴Piacenza Hospital, Piacenza, Italy, ⁵University Hospital of Bologna, Bologna, Italy, ⁶Fondazione IRCCS Policlinico, Pavia, Italy, ⁷Azienda ULSS N°9 Treviso, Treviso, Italy, ⁸GlaxoSmithKline Spa, Verona, Italy

PCV39	COST-EFFECTIVENESS OF NIASPAN® VERSUS ZETIA® AS ADD-ON TREATMENT TO STATIN THERAPY IN HIGH-RISK PATIENTS
	Sorensen SV¹, Webb SF², Burge RT²
	¹United BioSource Corporation, Bethesda, MD, USA, ²Abbott Laboratories, Abbott Park, IL, USA

PCV40	COST-EFFECTIVENESS OF TARGETING MULTIPLE LIPID PARAMETERS (LDL-C, HDL-C, TG) WITH NIASPAN® VERSUS A SINGLE LIPID PARAMETER (LDL-C) WITH ZETIA® IN PATIENTS RECEIVING ON-GOING STATIN THERAPY
	Sorensen SV¹, Webb SF², Burge RT²
	¹United BioSource Corporation, Bethesda, MD, USA, ²Abbott Laboratories, Abbott Park, IL, USA

PCV41	COST EFFECTIVENESS OF IMPLANTABLE LOOP RECORDER SYSTEM (REVEAL DX®) FROM THE SPANISH NHS PERSPECTIVE
	Garcia-Baena I¹, Rodriguez-Barrios JM², García García FJ³
	¹Universitat Pompeu Fabra, Barcelona, Spain, ²Medtronic Ibérica SA, Madrid, Spain, ³Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain

PCV42	COST-EFFECTIVENESS OF POPULATION-BASED ‘SCREEN-AND-TREAT' STRATEGIES DIRECTED AT ALBUMINURIA
	Boersma C¹, Gansevoort RT², Visser ST¹, De Jong-van den Berg L¹, de Jong PE², Postma M¹
	¹University of Groningen, Groningen, Netherlands, 2University Medical Center Groningen, Groningen, Groningen, Netherlands

PCV43	MODELED COST-EFFECTIVENESS OF ACHIEVING MULTIPLE LIPID TARGETS WHEN FENOFIBRIC ACID IS CO-ADMINISTERED WITH SIMVASTATIN, ROSUVASTATIN, AND ATORVASTATIN
	Webb SF¹, Burge RT², Sorensen SV³
	¹Abbott Laboratotires, Abbott Park, IL, USA, ²Abbott Laboratories, Abbott Park, IL, USA, ³United BioSource Corporation, Bethesda, MD, USA

PCV44	COST-EFFECTIVENESS MODEL OF IMPLANTABLE CARDIAC MONITORS (ICM) FOR PATIENTS TREATED WITH RADIOFREQUENCY CATHETER ABLATION FOR ATRIAL FIBRILLATION (PAAF) IN SPAIN
	Tsintzos S¹, Brosa M², Murthy A¹, Rodriguez JM³
	1Medtronic International, Tolochenaz, Switzerland, 2Oblikue Consulting, Barcelona, SC, Spain, 3Medtronic Iberia, Madrid, Spain

PCV45	COST-EFFECTIVENESS OF EPLERENONE IN PATIENTS WITH HEART FAILURE AFTER ACUTE MYOCARDIAL INFARCTION
	Martí-Sánchez D¹, Martí B², Sánchez-Maestre C²
	¹Cardiology Deparment, Hospital Ramón y Cajal, Madrid, Spain, ²Health Outcomes Research, Pfizer, Spain

PCV46	COST-EFFECTIVENESS OF CLOPIDOGREL IN MYOCARDIAL INFARCTION WITH ST-SEGMENT ELEVATION: A SPANISH MODEL BASED ON THE CLARITY AND COMMIT TRIALS
	Brosa M¹, Abadía C², Betegón L²
	¹Oblikue Consulting, Barcelona, SC, Spain, 2Sanofi-Aventis, Madrid, Spain

PCV47	ECONOMIC EVALUATION OF AN ABDOMINAL AORTIC ANEURYSM SCREENING PROGRAM
	Giardina S¹, Di Stasi F¹, Palombo D², Pane B2, Spinella G², Brasseur P³
	1Medtronic Italia, Sesto San Giovanni (MI), Italy, 2San Martino Hospital, Genova, Italy, 3Medtronic International SA, Tolochenaz, Switzerland

PCV48	ENHANCING SYNCOPE DIAGNOSTICS: COST-EFFECTIVENESS ANALYSIS OF AN IMPLANTABLE LOOP RECORDER STRATEGY VERSUS THE STANDARD OF CARE
	Van Genugten M¹, Tsintzos S²
	¹Medtronic Trading NL B.V, Heerlen, DA, Netherlands, ²Medtronic International Trading Sarl, Tolochenaz, Vaud, Switzerland

PCV49	COST-EFFECTIVENESS OF ATORVASTATIN 80 MG VS GENERIC SIMVASTATIN 20 TO 40 MG IN SECONDARY PREVENTION IN SPAIN
	Sánchez Maestre C¹, Martí B¹, Webb K², Soto J¹
	¹Health Outcomes Research, Pfizer, Spain, ²Pfizer Inc, Tadworth, Surrey, United Kingdom

EE5	COST-EFFECTIVENESS OF ATORVASTATIN IN TYPE 2 DIABETES PATIENTS : A PHARMACO-ECONOMIC ANALYSIS OF THE COLLABORATIVE ATORVASTATIN DIABETES STUDY (CARDS) IN THE BELGIAN POPULATION
	Marbaix S¹, Vandenberghe H¹, Van Gaal L²
	¹Pfizer WPO Belgium, Brussels, Belgium, ²Antwerp University Hospital, Edegem, Belgium

PCV50	COST-EFFECTIVENESS OF RULING OUT DEEP VENOUS THROMBOSIS IN PRIMARY CARE VERSUS CARE AS USUAL
	ten Cate - Hoek AJ1, Toll DB2, van der Velde EF3, Buller H3, Hoes AW2, Moons KG2, Oudega R2, Prins MH1, Stoffers HE1, van Weert HC3, Joore MA4
	1Maastricht University, Maastricht, Netherlands, 2University Medical Center Utrecht, Utrecht, Netherlands, 3Amsterdam Medical Centre, Amsterdam, Netherlands, 4University Hospital Maastricht, Maastricht, Netherlands

PCV51	SINGLE PILL AMLODIPINE/ATORVASTATIN IS COST-EFFECTIVE FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN KOREA
	Liew D1, Park HJ2, Ko S2
	1The University of Melbourne, Melbourne, Victoria, Australia, 2Pfizer Korea, Seoul, South Korea

PCV52	COST-UTILITY ANALYSIS OF HOME TELEMONITORING IN ELDERLY PATIENTS WITH CHRONIC HEART FAILURE
	Stafylas P1, Dafoulas G2, Aletras V3, Lashos V4, Raptis O2
	1AHEPA University Hospital, Thessaloniki, Greece, 2Telecare Center, Municipality of Trikala, Trikala, Greece, 3University of Macedonia, Thessaloniki, Greece, 4General Hospital of Trikala, Trikala, Greece

PCV53	DECISION ANALYTIC MODEL FOR GENETIC TESTING IN THE MANAGEMENT OF WARFARIN ANTICOAGULATION TREATMENT FOR HOSPITALIZED PATIENTS
	Moriarty J, Daniels P, Manning D, McBane R, Naessens J
	Mayo Clinic, Rochester, MN, USA

PCV54	A EUROPEAN MULTI-COUNTRY COMPARISON OF THE COST-EFFECTIVENESS OF IODIXANOL VERSUS IOHEXOL BASED ON THE RESULTS OF THE NEPHRIC CLINICAL TRIAL
	Patel P1, Zyczynski T2, Beard S3, Earnshaw SR4, McDade CL4, Zimovetz E3
	1GE Healthcare, Barrington, IL, USA, 2GE Healthcare, Princeton, NJ, USA, 3RTI Health Solutions, Manchester, United Kingdom, 4RTI Health Solutions, Research Triangle Park, NC, USA

PCV55	PHARMACOECONOMIC EVALUATION OF TREATMENT WITH PROCORALAN® PREPARATION COMPARED TO INVASIVE TREATMENT
	Filipiak KJ, Jaworski R
	Medical University of Warsaw, Warsaw, Poland

PCV56	AN ECONOMIC ANALYSIS OF INDUCTION OF LABOR AND EXPECTANT MANAGEMENT IN WOMEN WITH PREGNANCY- INDUCED HYPERTENSION OR PREECLAMPSIA AT TERM (HYPITAT TRIAL)
	Vijgen SM1, Opmeer BC1, Mol B1, Bijlenga D1, Burggraaff JM2, van Loon AJ3, Huisjes AJ4, Roumen FJ5, Papatsonis DN6, van Pampus MG7
	1Academic Medical Centre, Amsterdam, Netherlands, 2Scheper Hospital, Emmen, Netherlands, 3Martini Hospital, Groningen, Netherlands, 4Gelre Hospital, Apeldoorn, Netherlands, 5Atrium Medical Center, Heerlen, Netherlands, 6Amphia Hospital, Breda, Netherlands, 7University Medical Center, Groningen, Netherlands

PCV57	ESTIMATING THE NUMBER AND COST OF CARDIOVASCULAR EVENTS AVOIDED BY TREATING TO ALTERNATIVE LDL-C TARGETS: IS LOWER BETTER?
	Kingslake SL
	AstraZeneca UK Ltd, Luton, United Kingdom

PCV58	COSTS OF CORONARY ARTERY DISEASE (CAD) IN POLAND
	Banasiak W1, Jaworski R2, Pachocki R2
	14th Military Hospital, Wroclaw, Poland, 2Servier Polska, Warsaw, Poland

PCV59	INPATIENT RESOURCE USE ASSOCIATED WITH THE TREATMENT OF SECONDARY ATRIAL FIBRILLATION
	Spalding JR1, Exuzides A2, Adams S2, Colby C2, Noe L2
	1Astellas Pharma US, Deerfield, IL, USA, 2ICON Clinical Research, San Francisco, CA, USA

PCV60	TWO-YEAR HOSPITALIZATION RATES AND ASSOCIATED COSTS IN PATIENTS FROM GERMANY WITH PERIPHERAL ARTERIAL DISEASE: RESULTS FROM THE REDUCTION OF ATHEROTHROMBOSIS FOR CONTINUED HEALTH (REACH) REGISTRY
	Mahoney EM1, Lei Y1, Wang K1, Bruggenjurgen B2, Mosse F3, Parhofer KG4, Zeymer U5, Roether J6
	1Mid America Heart Institute of Saint Luke's Hospital, Kansas City, MO, USA, 2Alpha Care, Celle, Germany, 3Sanofi-Aventis, Paris, France, 4University Munich, Munich, Germany, 5Herzzentrum Ludwigshafen, Ludwigshafen, Germany, 6Johannes Wesling Klinikum Minden, Minden, Germany

PCV61	INFLUENCE THE CO-MORBIDITY AND DIRECT COSTS OF STROKE TO POPULATION SETTING AND IN CLINICAL PRACTICE
	Sicras-Mainar A1, Navarro-Artieda R2, Sánchez Maestre C3, Fernández de Bobadilla J4
	1Badalona Serveis Assistencials, Barcelona, Spain, 2Hospital Germans Trias y Pujol, Barcelona, Spain, 3Pfizer Spain, Madrid, Spain, 4Hospital de la Paz, Madrid, Spain

PCV62	THE BURDEN OF ACUTE CORONARY SYNDROMES IN AUSTRALIA
	Liew D1, Price N2
	1The University of Melbourne, Melbourne, Australia, 2Sanofi-Aventis Australia Pty Ltd, Sydney, Australia

PCV63	CO-MORBIDITY AND DIRECT COSTS ACCORDING THE CARDIOVASCULAR RISK LEVEL IN A SPANISH POPULATION SETTING
	Sicras A1, Navarro-Artieda R2, Sánchez Maestre C3, Martí B3
	1Badalona Servicios Asistenciales, Barcelona, Spain, 2Hospital Germans Trias y Pujol, Badalona, Barcelona, Spain, 3Health Outcomes Research, Pfizer, Spain

PCV64	INDEX, FOLLOW-UP AND TOTAL HOSPITALIZATION COSTS IN PATIENTS WITH ACUTE CORONARY SYNDROMES UNDERGOING PLANNED PERCUTANEOUS CORONARY INTERVENTION TREATED WITH PRASUGREL VS. CLOPIDOGREL IN THE TRITON-TIMI 38 TRIAL
	Mahoney EM1, Wang K2, Lei Y2, Arnold SV2, McCollam PL3, Riesmeyer J4, Plat F5, Cohen DJ2
	1Mid Americ Heart Institute of Saint Luke's Hospital, Kansas City, MO, USA, 2Mid America Heart Institute of Saint Luke's Hospital, Kansas City, MO, USA, 3Eli Lilly and Company, Indianapolis, IN, USA, 4Eli Lilly & Co, Indianapolis, IN, USA, 5Daiichi Sankyo, Edison, NJ, USA

PCV65	COSTS OF BLEEDS ASSOCIATED WITH TREATING ACUTE CORONARY SYNDROME PATIENTS IN GERMANY
	Bufe A1, Briswalter S2, Brown R3
	1Universitätsklinik der Universität Witten/Herdecke, Wuppertal, Wuppertal, Germany, 2GlaxoSmithKline, Munich, Germany, 3United BioSource Corporation, Bethesda, MD, USA

PCV66	WITHDRAWN



PCV67	CLINICAL CHARACTERISTICS, MEDICATION AND COSTS IN ACUTE HEART FAILURE PATIENTS IN THE CZECH REPUBLIC
	Ondrackova B1, Miklik R2, Parenica J2, Spinar J2, Pavlik T1, Tomcikova D1
	1Masaryk University, Brno, Czech Republic, 2Faculty Hospital Brno, Brno, Czech Republic

PCV68	IMPACT OF DRUG ELUTING STENTS ON CLINICAL AND ECONOMIC OUTCOMES IN AN UNSELECTED INTERVENTIONAL PRACTICE
	Rihal CS, Singh M, Bresnahan JF, Liesinger J, Gersh BJ, Long KH
	Mayo Clinic, Rochester, MN, USA

PCV69	COST-EFFECTVENESS OF ENDOVASCULAR ANEURYSM REPAIR VERSUS OPEN SURGICAL REPAIR: NON-RUPTURED INFRARENAL ABDOMINAL AORTIC ANEURYSM IN AN ELECTIVE SETTING
	Hayes P1, Ryan J2, Jensen M2, Harrison L2, Wyatt M3, Bradbury A4, Brasseur P5
	1Addenbrooke's Hospital, Cambridge, United Kingdom, 2Abacus International, Bicester, United Kingdom, 3Freeman Hospital, Newcastle upon Tyne, United Kingdom, 4University of Birmingham, Birmingham, United Kingdom, 5Medtronic Europe Sàrl, Tolochenaz, Switzerland

PCV70	COST-EFFECTIVENESS OF CLOPIDOGREL IN COMBINATION WITH ASPIRIN FOR ACUTE CORONARY SYNDROMES IN AUSTRALIA
	Liew D1, Cordony A2
	1The University of Melbourne, Melbourne, Victoria, Australia, 2Sanofi-Aventis Australia, Macquarie Park, NSW, Australia

PCV71	COST-UTILITY ANALYSIS IN PATIENTS WITH DRUG REFRACTORY CONCOMITANT ATRIAL FIBRILLATION IN SPAIN
	López Gude MJ1, Rodríguez Bezos D2, Rodríguez Barrios JM2, Serrano Contreras D2
	1Hospital 12 Octubre, Madrid, Spain, 2Medtronic Iberia, Madrid, Spain

PCV72	COST/UTILITY ANALYSIS (CUA) OF VALSARTAN FOR THE TREATMENT OF CONGESTIVE HEART FAILURE (CHF) IN ITALY BASED ON THE VAL-HEFT TRIAL
	Pradelli L, Iannazzo S, Zaniolo O
	AdRes Srl, Turin, Italy

PCV73	COST-EFFECTVENESS OF ENDOVASCULAR ANEURYSM REPAIR VERSUS OPEN SURGICAL REPAIR: ACUTE INFRARENAL ABDOMINAL AORTIC ANEURYSM IN AN EMERGENCY SETTING
	Hayes P1, Ryan J2, Jensen M2, Harrison L2, Brasseur P3
	1Addenbrooke's Hospital, Cambridge, United Kingdom, 2Abacus International, Bicester, United Kingdom, 3Medtronic Europe Sàrl, Tolochenaz, Switzerland

PCV74	COST-EFFECTIVENESS OF DABIGATRAN ETEXILATE FOR THE PRIMARY PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING TOTAL HIP OR TOTAL KNEE REPLACEMENT SURGERY
	Wolowacz S1, Roskell N1, Maciver F1, Beard S1, Robinson P2, Plumb J3
	1RTI Health Solutions, Manchester, United Kingdom, 2Boehringer Ingelheim Ltd, Bracknell, United Kingdom, 3Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany

PCV75	THE IMPACT OF POSTPRANDIAL PEAKS ON CARDIOVASCULAR COMPLICATIONS BEYOND THE HBA1C LEVEL - A HEALTH ECONOMIC ASSESSMENT
	Neeser K, Heister F, Weber C
	Institute for Medical Informatics and Biostatistics, Basel, Switzerland

PCV76	THE KOREAN INDIVIDUAL-MICROSIMULATION MODEL FOR CARDIOVASCULAR HEALTH INTERVENTIONS (KIMCHI)
	Liew D1, Ko S2, Kang HY3
	1The University of Melbourne, Melbourne, Victoria, Australia, 2Pfizer Korea, Seoul, South Korea, 3Yonsei University, Seoul, South Korea

PCV77	COST EFFECTIVENESS OF HIGH DOSE ATORVASTATIN IN ACUTE CORONARY SYNDROME PATIENTS IN THE UK
	Thurston SJ1, Thompson RP2, Ong S2, van Hout BA1
	1Pharmerit Ltd, York, North Yorkshire, United Kingdom, 2Pfizer Ltd, Tadworth, Surrey, United Kingdom

PCV78	ANEURYSM OCCLUSION IN ELDERLY PATIENTS WITH ANEURYSMAL SUBARACHNOID HAEMORRHAGE: A COST-UTILITY ANALYSIS
	Koffijberg H1, Buskens E2, Rinkel G1
	1University Medical Center Utrecht, Utrecht, Netherlands, 2University Medical Center Groningen, University of Groningen, Groningen, Netherlands

PCV79	ECONOMIC EVALUATION OF IRBESARTAN IN GREECE
	Maniadakis N1, Fragoulakis V2, Papagiannopoulou V3, Yfantopoulos I3
	1University of Piraeus, Drosia, Greece, 2National Social Insurance Institute, Athens, Greece, 3University of Athens, Athens, Greece

PCV80	TISSUE ENGINEERING OF VALVED VENOUS CONDUITS (VVC) VERSUS CONSERVATIVE THERAPY IN PATIENTS WITH CHRONIC VENOUS INSUFFICIENCY (CVI). A DECISION ANALYTIC MODEL USING EXPERT ESTIMATED UTILITIES BASED ON DERIVED DATA FROM ANIMAL STUDIES AS A PRE-MARKETING TECHNOLOGY ASSESSMENT APPROACH WITH GERMAN DATA
	Dintsios CM1, Hagen A2, Gerhardus A3, Krauth C4
	1Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany, 2Hannover Medical Scholl, Hannover, Germany, 3University of Bielefeld, Bielefeld, Germany, 4Hannover Medical School, Hannover, Germany

PCV81	AN ECONOMIC EVALUATION OF THE ADDITION OF FIXED-DOSE NIACIN EXTENDED-RELEASE AND SIMVASTATIN THERAPY TO THE MANAGED CARE FORMULARY IN TERMS OF OPTIMAL LIPID VALUE ATTAINMENT
	Balu S1, Simko RJ1, Burge RT1, Cziraky MJ2, Quimbo R2
	1Abbott Labs, Abbott Park, IL, USA, 2HealthCore, Inc, Wilmington, DE, USA

PCV82	CHANGE IN LIPID VALUES, TARGET LIPID VALUE ATTAINMENT, AND ANNUAL HEALTH CARE RESOURCE UTILIZATION AND COSTS AMONG PATIENTS INITIATING COMBINATION STATIN AND EXTENDED-RELEASE NIACIN THERAPY
	Simko RJ1, Burge RT1, Balu S1, Tunceli O2, Quimbo R2, Cziraky MJ2
	1Abbott Laboratories, Abbott Park, IL, USA, 2HealthCore, Inc, Wilmington, DE, USA

PCV83	AN EVALUATION OF THE INCREMENTAL CHANGE IN THE INCIDENCE OF CARDIOVASCULAR EVENTS AND RELATED COSTS WITH THE ADDITION OF FIXED-DOSE NIACIN EXTENDED-RELEASE AND SIMVASTATIN THERAPY TO THE MANAGED CARE FORMULARY
	Balu S1, Simko RJ2, Burge RT2, Cziraky MJ3, Quimbo R3
	1Abbott Labs, Abbott Park, IL, USA, 2Abbott Laboratories, Abbott Park, IL, USA, 3HealthCore, Inc, Wilmington, DE, USA

PCV84	HEALTH CARE RESOURCES AND QUALITY OF LIFE IN ACUTE CORONARY SYNDROME PATIENTS IN 2007: FRENCH BASELINE RESULTS FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL STUDY (APTOR)
	Ferrieres J1, Tcherny-Lessenot S2, Sartral M3, Pentel J2, Delahais V2
	1CHU Rangueil, Toulouse, France, 2Lilly France, Suresnes, France, 3Eli Lilly and Company Ltd, Suregnes, France

PCV85	STROKE PATIENT RESOURCE USE AND CAREGIVER BURDEN OUTCOMES BY SEVERITY (RECOVERY) STUDY: METHODS AND RESULTS FROM THE ATHENS STROKE REGISTRY
	Payne K1, Caro JJ2, Lordan N2, Huybrechts KF2, Ishak KJ1, Rylander A3, Vemnos K4
	1United BioSource Corporation, Montreal, QC, Canada, 2United BioSource Corporation, Concord, MA, USA, 3AstraZeneca Sweden AB, Sodertalje, Sweden, 4University of Athens School of Medicine; Alexandra Hospital, Athens, Greece

CARDIOVASCULAR DISORDERSPatient-Reported Outcomes Studies
PCV86	COMPARISON OF PERSISTENCE AND ADHERENCE BETWEEN PRASUGREL AND CLOPIDOGREL IN THE TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROMES AND PERCUTANEOUS CORONARY INTERVENTIONS
	Bae JP¹, Zhu B¹, McCollam PL¹, Ramaswamy K², Johnston JA¹, Cohen DJ³, Effron MB¹
	¹Eli Lilly and Company, Indianapolis, IN, USA, ²Daiichi Sankyo Inc, Parsippany, NJ, USA, ³Mid America Heart Institute of Saint Luke's Hospital, Kansas City, MO, USA

PCV87	PERSISTENCE WITH AMIODARONE OR SOTALOL AND ITS IMPACT ON ATRIAL FIBRILLATION-RELATED HOSPITALIZATIONS AND CARDIOVERSIONS
	Ishak KJ¹, Proskorovsky I², Guo S³, Lin J⁴, Caro JJ³
	¹United BioSource Corporation, Montreal, QC, Canada, ²United BioSource Corporation, Dorval, Quebec, Canada, ³United BioSource Corporation, Concord, MA, USA, ⁴Sanofi-Aventis US, Bridgewater, NJ, USA

PCV88	IMPACT OF SINGLE-PILL VS. 2-PILL AMLODIPIN/ATORVASTATIN TREATMENT ON COMPLIANCE: A CZECH PILOT PROJECT ON MEDICATION ADHERENCE
	Cerna V, Skoupá J
	Pharma Projects, Prague, Czech Republic

PCV89	THE COST EFFECTIVENESS OF PERSISTENCE TO ANTIHYPERTENSIVE TREATMENT
	Jorgensen E¹, Paulsson T²
	¹AstraZeneca Norway, Oslo, Norway, ²AstraZeneca, Södertälje, Sweden

PCV90	THE CONTRIBUTION OF THE MEASUREMENT OF TREATMENT ACCEPTABILITY TO UNDERSTAND PATIENTS' ADHERENCE TO LONG-TERM TREATMENTS. RESULTS FROM A FEASIBILITY STUDY CONDUCTED WITH IN FINE PHARMA®: A COMMUNITY-PHARMACY NETWORK DEDICATED TO PHARMACOEPIDEMIOLOGICAL SURVEYS
	Saussier C¹, Van Ganse E², Augé-Caumon MJ³, Chamba G⁴, Marrel A¹, Benmedjahed K⁵, Longin J¹
	¹MAPI, Lyon, France, ²Pierre Wertheimer Hospital, Bron, France, ³USPO, Paris, France, ⁴Pharmakeion, Lyon, France, ⁵Mapi Values, Lyon, France

PCV91	IMPACT OF CATHETER ABLATION VERSUS ANTIARRHYTHMIC DRUGS ON QUALITY OF LIFE IN PATIENTS WITH ATRIAL FIBRILLATION
	Bulkova V¹, Fiala M², Wichterle D¹, Haman L³, Chovancik J², Simek J¹, Parizek P³, Wojnarova D², Havranek S¹
	¹Department of Cardiology and Angiology, First Faculty of Medicine Charles University School in Prague, Prague, Czech Republic, ²Department of Cardiology, Hospital Podlesi, Trinec, Czech Republic, ³Department of Cardiology, University Hospital, Hradec Kralove, Hradec Kralove, Czech Republic

PCV92	DERIVING UTILITY VALUES FOR ACUTE CORONARY SYNDROMES FROM THE GENERAL POPULATION IN AUSTRALIA
	Cordony A, Price N, Gonzalo F, Yuen C
	Sanofi-Aventis Australia, Macquarie Park, NSW, Australia

PCV93	FACTORS DETERMINING UTILITY MEASURED WITH THE EQ-5D IN PATIENTS WITH ATRIAL FIBRILLATION
	Berg J¹, Lindgren P¹, Nieuwlaat R², Bascle S³, Crijns H⁴
	¹i3 Innovus, Stockholm, Sweden, ²Population Health Research Institute, Hamilton, ON, Canada, ³Sanofi-Aventis, Paris, France, ⁴University Hospital Maastricht, Maastricht, Netherlands

PCV94	PREDICTORS OF HEALTH STATUS CHANGE AMONG PATIENTS TREATED WITH A CALCIUM ANTAGONIST- OR AN ATENOLOL-LED HYPERTENSION STRATEGY IN THE INTERNATIONAL VERAPAMIL SR-TRANDOLAPRIL STUDY (INVEST)
	Ried LD, Gandhi PK, Bibbey A
	University of Florida, Gainesville, FL, USA

PCV95	SOCIODEMOGRAPHIC AND CARDIOVASCULAR RISK FACTORS INFLUENCES ON EQ-5D SOCIAL PREFERENCES SCORES AND SELF-REPORTED HEALTH: A GENERAL POPULATION SURVEY IN ARGENTINA
	Augustovski FA, Irazola V, Caporale JE, Rubinstein A
	Instituto de Efectividad Clínica y Sanitaria (IECS), Buenos Aires, Argentina

PCV96	ACCEPTABILITY OF TECHNOLOGICAL TREATMENT AND THE EFFECT OF RESPONDENT CHARACTERISTICS ON TREATMENT PREFERENCE
	van Til JA, IJzerman MJ
	University of Twente, Enschede, Netherlands

PCV97	TREATMENTS FOR VARICOSE VEIN DISEASE: EXPECTATIONS AND EXPERIENCES OF PATIENTS
	Spijkers CJ¹, Dirksen CD¹, Krabbe PFM², Dellaert BGC³, Severens JL¹, Sommer A¹, Joore MA¹
	¹University Hospital Maastricht, Maastricht, Netherlands, ²Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Erasmus University Rotterdam, Rotterdam, Netherlands

PCV98	MODELLING THE EFFECT OF DIAGNOSTIC STRATEGIES IN PATIENTS WITH SUSPECTED CORONARY ARTERY DISEASE (CAD) ON CAPACITY AND PRODUCTIVITY OF CORONARY DIAGNOSTIC FACILITIES IN THE UNITED KINGDOM
	Barwell T¹, Patel P², Marelli C³
	¹Abacus International, Bicester, United Kingdom, ²GE Healthcare, Barrington, IL, USA, ³GE Healthcare, Chalfont St Giles, United Kingdom

CARDIOVASCULAR DISORDERSHealth Care Use & Policy Studies
PCV99	A CROSS-NATIONAL COMPARISON ON PRICES OF PHARMACEUTICAL PRODUCT
	Sakamaki H
	Meijo University, Nagoya, Japan

PCV100	METFORMIN FOR THE TREATMENT OF METABOLIC DISTURBANCES AND CARDIOVASCULAR RISK FACTORS IN WOMEN WITH POLYCYSTIC OVARY SYNDROME: A SYSTEMATIC REVIEW AND META-ANALYSIS
	Bouza C, Lopez T, Ruiz M
	Carlos III Health Institute, Madrid, Spain

PCV101	PROSPECTIVE STUDY TO EVALUATE THE IMPACT OF A DISEASE EDUCATION PROGRAM OF CARDIOVASCULAR RISK CONTROL IN HYPERTENSION
	Galera J¹, Salazar J¹, Armario P², Segura J³
	¹Novartis Farmacéutica S.A, Barcelona, Spain, ²Hospital General de L'Hospitalet, L'Hospitalet de Llobregat (Barcelona), Spain, ³Hospital 12 de Octubre, Madrid, Spain

PCV102	COST-EFFECTIVENESS OF MANAGING ORAL ANTICOUAGULATION (OAC) AFTER CATHETER ABLATION FOR ATRIAL FIBRILLATION (PAAF) WITH IMPLANTABLE CARDIAC MONITORS (ICMS)
	Tsintzos S¹, Murthy A²
	¹Medtronic International Trading Sarl, Tolochenaz, Vaud, Switzerland, ²Medtronic International, Tolochenaz, Vaud, Switzerland

PCV103	TECHNOLOGICAL INNOVATION AND THE DECISION-MAKING PROCESS IN ITALIAN HOSPITALS
	Bartoli S¹, Tarricone R¹, Benussi S², Stefano P³, Marinelli G⁴
	¹Bocconi University, Milan, Italy, ²S Raffaele University Hospital, Milan, Italy, ³Careggi University-Hospital, Firenze, Italy, ⁴Sant'Orsola-Malpighi University-Hospital, Bologna, Italy

PCV104	EVALUATION OF THE PRESCRIPTION PATTERNS OF STATINS THROUGH APPROPRIATE INDICATORS IN TWO ITALIAN LOCAL HEALTH UNITS IN 2004-2006
	Lopatriello S¹, Salvato C², Maccari D², Palcic S³, Broussard P³, Negrini C⁴
	¹Pbe Consulting, Verona, Italy, ²ASL 7 Pieve di Soligo (TV), Pieve di Soligo, Italy, ³A.S.S. 1 “Triestina”, S.C. Assistenza farmaceutica, Trieste, Italy, ⁴Pbe Consulting, Milano, Italy

PCV105	STATIN PRESCRIBING IN THE CITY OF ZAGREB (2001-2006) AND THEIR ROLE IN SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS
	ŠTimac D, Culig J
	Zagreb institute of Public Health, Zagreb, Croatia

PCV106	PATIENT OUTCOMES AND HEALTH ECONOMICS ASSOCIATED WITH THE USE OF OCTYLCYANOACROLATE TOPICAL SKIN ADHESIVE IN CABG SURGERY
	Fraeman KH¹, Reynolds MW², Vaughn B³, De Lissovoy G¹
	¹United BioSource Corporation, Bethesda, MD, USA, ²United BioSource Corp, Medford, MA, USA, ³ETHICON, Inc, Somerville, NJ, USA

PCV107	CLOPIDOGREL PATTERNS OF USE IN ACUTE CORONARY SYNDROME PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN FIVE EUROPEAN COUNTRIES
	McCollam PL¹, Bae JP¹, Nasuti P², Anger C³
	¹Eli Lilly and Company, Indianapolis, IN, USA, ²IMS Hospital Group Ltd, Sittingbourne, United Kingdom, ³IMS Health, Kent, United Kingdom

PCV108	RISK AND COSTS OF THE FIRST HYPERTENSION-ASSOCIATED EVENT, COMPLIANCE AND PERSISTENCE IN NAÏVE HYPERTENSIVE PATIENTS AFTER INITIATING MONOTHERAPY
	Mathes J¹, Kostev K², Gabriel A¹, Pirk O¹, Schmieder RE³
	¹IMS HEALTH, Nuremberg, Germany, ²IMS HEALTH, Frankfurt am Main, Germany, ³Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany

PCV109	PRESCRIPTION DRUG INSURANCE AND EX ANTE MORAL HAZARD
	Khan N¹, Kaestner R²
	¹University of New Mexico, Albuquerque, NM, USA, ²University of Illinois at Chicago, Chicago, IL, USA

PCV110	THE POTENTIAL ECONOMIC IMPACTS OF RECONFIGURING TIA CARE IN THE UK
	Jackson D¹, Begg A², Moshinsky J²
	¹GE Healthcare, Bucks, United Kingdom, ²Medaxial Group, London, United Kingdom

PCV111	COST- ANALYSIS OF DYSLIPOPROTEINAEMIA TREATMENTS WITHIN THE SLOVAK REPUBLIC
	Tesar T¹, Foltan V¹, Ilavska A²
	¹Comenius University, Bratislava, Slovak Republic, ²Railway Hospital, Bratislava, Slovak Republic

PCV112	STATINS USE IN PATIENTS WITH A RECENT ISCHEMIC STROKE : RESULTS FROM THE STROKE ANALYZER DATABASE
	Nasuti P, Belilty J, Hamad B
	IMS Health, London, United Kingdom

PCV113	PATIENTS WITH ACUTE ST-ELEVATION MYOCARDIAL INFARCTION: WHO ARE THE “UNTREATED PATIENTS” IN HOSPITALS WITH CATH LAB?
	Hamad B, Nasuti PI, Belilty J
	IMS Health, London, United Kingdom

PCV114	SEARCHING THE OPTIMAL TREATMENT MIX STRATEGY WITH A TREATMENT MIX CHART APPROACH – THE CASE OF CHOLESTEROL LOWERING IN SWEDEN
	Martikainen JA¹, Soini EJ¹, Paulsson T²
	¹ESiOR Oy, Kuopio, Finland, ²AstraZeneca, Södertälje, Sweden

PCV115	ASSESSING THE POTENTIAL BENEFITS OF CHANGING REIMBURSEMENT CRITERIA FOR LIPID LOWERING THERAPY IN KOREA
	Kang HY¹, Liew D², Ko S³, Kim J⁴
	¹Yonsei University, Seoul, South Korea, ²The University of Melbourne, Melbourne, Victoria, Australia, ³Pfizer Korea, Seoul, South Korea, ⁴Konyang University, Chungnam, South Korea

PCV116	THE ANALYSIS OF STATINS USAGE IN CROATIA DURING THE FIVE-YEAR PERIOD
	Vitezic D¹, Buble T², Matana Kastelan Z³, Kovacevic M⁴, Mrsic Pelcic J⁵
	¹University of Rijeka Medical School and University Hospital Centre Rijeka, Rijeka, Croatia, ²Croatian National Health Insurance, Zagreb, Croatia, ³University of Rijeka School of Medicine, Rijeka, Croatia, ⁴University Hospital Centre Rijeka and University of Rijeka School of Medicine, Rijeka, Croatia, ⁵University of Rijeka Medical School, Rijeka, Croatia

PCV117	COMPARATIVE ANALYSIS OF HEALTH TECHNOLOGY ASSESSMENTS (HTA) OF DRUG ELUTING STENTS (DES)
	Hurry MV¹, Bending MW¹, Trueman P¹, Hutton J¹, Brasseur P²
	¹University of York, York, North Yorkshire, United Kingdom, ²Medtronic Europe Sàrl, Tolochenaz, Switzerland

PCV118	ADVANCING SYNCOPE DIAGNOSIS THROUGH IMPLANTABLE LOOP RECORDERS (ILRS) IN SWEDEN: COST-EFFECTIVENESS ANALYSIS OF NEW DIAGNOSTIC STRATEGIES
	Gadler F¹, Murthy A², Sohlberg A³, Tsintzos S⁴
	¹Karolinska Hospital, Stockholm, Sweden, ²Medtronic International, Tolochenaz, Vaud, Switzerland, ³Medtronic International, Stockholm, Sweden, ⁴Medtronic International Trading Sarl, Tolochenaz, Vaud, Switzerland

	Rodriguez Barrios JM¹, Moreu J², Cequier A³, Brosa M⁴, Vazquez N⁵, Hernandez J⁶, Crespo C⁷, Brasseur P⁸
	¹Medtronic Iberia, Madrid, Madrid, Spain, ²Virgen de la Salud Hospital, Toledo, Toledo, Spain, ³Belvitge Hospital, Barcelona, Barcelona, Spain, ⁴Oblikue, Barcelona, Barcelona, Spain, ⁵Juan Canalejo Hospital, A Coruna, A Coruna, Spain, ⁶Malaga Clinic Hospital, Malaga, Malaga, Spain, ⁷Oblikue Consulting, Barcelona, Spain, ⁸Medtronic Sarl, Tolochenaz, Switzerland

PCV120	GLYCOPROTEIN INHIBITOR USE IN ACUTE CORONARY SYNDROME PATIENTS IN 2007: RESULTS FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL STUDY (APTOR)
	Zeymer U¹, Leidreiter K², Bakhai A³, Iniguez Romo A⁴, Ferrieres J⁵
	¹Klinikum Ludwigshafen, Ludwigshafen, Germany, ²Eli Lilly Export S.A, Vernier/Geneva, Switzerland, ³Barnet & Chase Farm NHS Trust, Barnet, United Kingdom, ⁴Hospital Meixoeiro, Vigo, Spain, ⁵CHU Rangueil, Toulouse, France

PCV121	LIPID MANAGEMENT OF HIGH RISK PATIENTS IN THE OUTPATIENT SETTING IN GERMANY: RESULTS OF DYSIS-GERMANY
	Gitt AK¹, Smolka W², Bestehorn K²
	¹University of Heidelberg, Ludwigshafen, Germany, ²MSD Germany, Haar, Germany

CARDIOVASCULAR DISORDERSConceptual Papers & Research on Methods
PCV122	MODELING THE EFFECT OF DIFFERENTIAL COMPLIANCE WITH ANTIHYPERTENSIVE DRUGS ON CLINICAL ENDPOINTS
	Lowy A¹, Nixon R¹, Ong SH¹, Munk V¹, Turk F¹, Keefe D², Vincze G¹
	¹Novartis Pharma AG, Basel, Switzerland, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

PCV123	THE CARDIOVASCULAR PREVENTION MODEL (CPM), A GENERICALLY APPLICABLE MODEL FOR UNDERTAKING COST-EFFECTIVENESS ANALYSES OF PREVENTIVE INTERVENTIONS
	Liew D¹, Nanayakkara S², Webb K³, Grobler M⁴, Delahoy PJ⁵, Magliano DJ⁶
	¹The University of Melbourne, Melbourne, Victoria, Australia, ²Monash University, Melbourne, Victoria, Australia, ³Pfizer Inc, Tadworth, Surrey, United Kingdom, ⁴Pfizer Australia Pty Ltd, Sydney, NSW, Australia, ⁵Pfizer Australia Pty Ltd, West Ryde, NSW, Australia, ⁶International Diabetes Institute, Melbourne, Victoria, Australia

HEALTH CARE USE & POLICY STUDIES Consumer Role in Health Care
PHP1	PATIENTS' PREFERENCES FOR AND PRICE ELASTICITY OF GENERIC AND BRANDED OVER-THE-COUNTER MEDICINES - AN ADAPTIVE CONJOINT ANALYSIS (ACA) APPROACH
	Linden K¹, Halme ML²
	¹Pfizer Oy, Helsinki, Finland, ²Helsinki School of Economics, Helsinki, Finland

PHP2	CONSUMERS' PERCEPTIONS OF DRUG EFFECTIVENESS AND PRICES IN GREECE
	Tsiantou V¹, Roubou I², Pavi E¹, Kyriopoulos J¹
	¹National School of Public Health, Athens, Greece, ²NOVARTIS (HELLAS) S.A.C.I, Athens, Greece

PHP3	INNOVATIVE HEALTH TECHNOLOGIES IN THE “ANTI-AGING-MEDICINE” FIELD: RESULTS FROM A SYSTEMATIC HORIZON SCANNING
	Storz P, Gothe H, Daroszewska A, Häussler B
	IGES Institut GmbH, Berlin, Germany

PHP4	PATIENT PREFERENCES TOWARD HEALTH SERVICES PROVIDED BY THE GENERAL PRACTIONER
	Pezij JW¹, Bredenhoff E¹, Bridges J², Vrenken R³, IJzerman MJ¹
	¹University of Twente, Enschede, Netherlands, ²Johns Hopkins University, Baltimore, MD, USA, ³Healthcenter "de Oosterpoort", Enschede, Netherlands

PHP5	HEALTH LITERACY – AN ECONOMIC PERSPECTIVE: A SYSTEMATIC REVIEW
	Eichler K, Wieser S, Brügger U
	Zurich University of Applied Sciences, Winterthur, Switzerland

HEALTH CARE USE & POLICY STUDIES Diagnosis Related Group
PHP6	CLINICAL AND ECONOMIC OUTCOME OF MECHANICALLY VENTILATED PATIENTS UNDER DRG 483 IN SPAIN: A POPULATION-BASED STUDY
	Bouza C, Lopez T, Muñoz R
	Carlos III Health Institute, Madrid, Spain
PHP7	COMPARING THE ACTUAL HOSPITAL COST OF A PATIENT WITH ESOPHAGEAL CANCER TO NORMATIVE DRG REIMBURSEMENT
	Varga S¹, Bogár L¹, Sebestyen A², Kriszbacher I¹, Vas G¹, Boncz I¹
	¹University of Pecs, Pecs, Hungary, ²National Health Insurance Fund Administration, Pecs, Hungary
PHP8	ADVERSE DRUG REACTIONS IN GERMANY: COST ANALYSIS OF INTERNAL MEDICINE HOSPITALIZATIONS
	Rottenkolber D¹, Rottenkolber M², Schmiedl S³, Szymanski J³, Hasford J²
	¹Munich Center of Health Sciences, Munich, Germany, ²Ludwig-Maximilians-Universität, Munich, Germany, ³University of Witten/Herdecke, HELIOS Klinikum Wuppertal, Wuppertal, Germany


HEALTH CARE USE & POLICY STUDIES Drug/Device/Diagnostic Use & Policy
PHP9	DELAY OF DECISION-MAKING ON PHARMACEUTICAL REIMBURSEMENT IN NORMAL PROCEDURE IN HUNGARY
	Nagy Z¹, Molnár MP², Sebestyen A³, Kriszbacher I⁴, Vas G⁴, Boncz I⁴
	¹Health Insurance Supervisory Authority, Budapest, Hungary, ²National Health Insurance Fund Administration (OEP), Budapest, Hungary, ³National Health Insurance Fund Administration, Pecs, Hungary, ⁴University of Pecs, Pecs, Hungary

PHP10	PHARMACY AND HOSPITAL MARKET PERFORMANCE INDICATORS IN FINLAND 1995-2007
	Jormanainen V, Kannisto H, Mäntyranta T
	Centre for Pharmacotherapy Development, Helsinki, Finland

PHP11	WITHDRAWN



PHP12	THE BELGIAN REIMBURSEMENT PROCEDURE (BRP): ARE ADDED THERAPEUTIC VALUE (ATV) AND ICER AFFECTING THE DRUG REIMBURSEMENT DECISION (DRD)?
	Verplanken P¹, Arickx F¹, Bormans V¹, Soete E¹, Annemans L², Robays H³, Van Wilder P¹
	¹RIZIV-INAMI National Health Insurance Agency, Brussels, Belgium, ²University of Ghent, Brussels University, Ghent, Belgium, ³Ghent University, Grimbergen, Belgium

PHP13	MARKET AUTHORIZATION (MA) AND REIMBURSEMENT: ANALYSIS OF THE POST-MA TIMELINES AND THE ACCESS TO NEW MEDICINES IN BELGIUM
	Arickx F, Pierlet M, Soete E, VanHaeren E, Verplanken P, Van Wilder P
	RIZIV INAMI National Health Insurance Agency, Brussels, Belgium

PHP14	THE COMPETITIVE ACQUISITION PROGRAM (CAP): WHERE IS IT AFTER TWO YEARS?
	Pierce CA
	The Resource Group, Richfield, OH, USA

PHP15	DETERMINANTS OF PHARMACEUTICAL CONSUMPTION IN A GENERAL POPULATION
	Pappa E¹, Kontodimopoulos N¹, Papadopoulos AA², Tountas Y³, Niakas D¹
	¹Hellenic Open University, Patras, Greece, ²Attikon University Hospital, Athens, Greece, ³University of Athens, Athens, Greece

PHP16	OUTHOSPITAL DRUG CONSUMPTION IN MONTENEGRO IN 2007.
	Tomic Z¹, Sabo A¹, Vukmirovic S¹, Milijasevic B¹, Satman M², Golocorbin Kohn S¹, Mikov M¹
	¹Medical faculty of Novi Sad, Novi Sad, Serbia and Montenegro, ²Drug Agency Montenegro, Podgorica, Yugoslavia

PHP17	SOURCES OF INFORMATION ON DRUGS USED BY GENERAL PRACTITIONERS IN POLAND
	Ułanowski P, Jakubczyk M, Hermanowski T
	Department of Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland

PHP18	COMPARISON OF COST/QALY RATIO IN DIAGNOSTIC AND THERAPEUTIC DEVICES OR DRUGS
	Rodríguez Bezos D, Serrano D, Rodríguez Barrios JM
	Medtronic Iberica, Madrid, Madrid, Spain

HEALTH CARE USE & POLICY STUDIESEquity and Access
PHP19	REGIONAL MARKET ACCESS INEQUALITIES FOR NEW ONCOLOGY DRUGS IN SPAIN
	Vieta A, Gimenez E, Badia X
	IMS Health, Barcelona, Spain

PHP20	THE EFFECT OF THE INTRODUCTION OF HOSPITAL DAILY FEE ON THE NUMBER OF ADMISSIONS TO ACUTE CARE HOSPITAL WARDS IN HUNGARY
	Nagy J¹, Kövi R², Sebestyen A³, Kiss Z², Molnár A², Kőrösi L², Kriszbacher I⁴, Betlehem J⁴, Boncz I⁴
	¹National Health Insurance Fund, Budapest, Hungary, ²National Health Insurance Fund Administration (OEP), Budapest, Hungary, ³National Health Insurance Fund Administration, Pecs, Hungary, ⁴University of Pecs, Pecs, Hungary

PHP21	THE EFFECT OF THE INTRODUCTION OF VISIT FEE ON THE NUMBER OF PATIENT-VISITS TO OUTPATIENT CARE DEPARTMENTS IN HUNGARY
	Boncz I¹, Nagy J², Kőrösi L³, Kövi R³, Molnár A³, Kiss Z³, Kriszbacher I¹, Varga S¹, Sebestyen A⁴
	¹University of Pecs, Pecs, Hungary, ²National Health Insurance Fund, Budapest, Hungary, ³National Health Insurance Fund Administration (OEP), Budapest, Hungary, ⁴National Health Insurance Fund Administration, Pecs, Hungary

PHP22	COMPARATIVE ANALYSIS OF HOSPITAL BED CAPACITITES OF OLD (EU-15) AND NEW (EU-12) MEMBERSTATES OF THE EUROPEAN UNION
	Vas G¹, Sebestyen A², Ágoston I¹, Varga S¹, Kriszbacher I¹, Betlehem J¹, Boncz I¹
	¹University of Pecs, Pecs, Hungary, ²National Health Insurance Fund Administration, Pecs, Hungary

PHP23	CHARACTERISTICS OF UTILIZATION OF PRIMARY CARE OF GENERAL PRACTITIONERS IN COUNTY BARANYA IN HUNGARY
	Sebestyen A¹, Lipp S¹, Kriszbacher I², Betlehem J², Kiss Z³, Molnár A³, Kõrösi L³, Boncz I²
	¹National Health Insurance Fund Administration, Pecs, Hungary, ²University of Pecs, Pecs, Hungary, ³National Health Insurance Fund Administration, Budapest, Hungary

HEALTH CARE USE & POLICY STUDIESFormulary Development
PHP24	USE OF THE AMCP FORMAT IN THE U.S.: A NATIONAL SURVEY OF HEALTH PLANS
	Neumann PJ¹, Sullivan SD², Schur C³, Gupta J⁴, Berk M³
	¹Tufts Medical Center, Boston, MA, USA, ²University of Washington, Seattle, WA, USA, ³Social and Scientific Systems, Silver Springs, MD, USA, ⁴Social & Scientific Systems, Silver Springs, MD, USA

PHP25	EVALUATING AN ONLINE FREEWARE CALCULATOR AND PLOTTER FOR ANALYZING COST EFFECTIVENESS DATA FOR FORMULARY DRUG CLASSES
	McGhan WF, Peterson AM
	University of the Sciences, Philadelphia, PA, USA

PHP26	WITHDRAWN



PHP27	WITHDRAWN

HEALTH CARE USE & POLICY STUDIESHealth Care Costs & Management
PHP28	A COMPARISON OF HIGH-COST HEALTH CARE PROGRAMS AVAILABLE IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM
	Saggia MG
	Roche Brazil, Sao Paulo, SP, Brazil

PHP29	MICROCOSTING STUDY OF THE DAILY ICU COSTS IN THREE COUNTRIES
	Tan S¹, Martin J², Pezzi A³, Bakker J¹, Neurohr C⁴, Pitrelli A⁵, Hakkaart L¹, Welte R⁴
	¹Erasmus MC University Medical Center, Rotterdam, Netherlands, ²Kliniken des Landkreises Göppingen gGmbH, Göppingen, Germany, ³Università degli Studi di Milano, Milan, Italy, ⁴GlaxoSmithKline, Munich, Germany, ⁵GlaxoSmithKline spa, Verona, Veneto, Italy

PHP30	COST DRIVERS IN THE PHARMACEUTICAL MARKET IN GERMANY IN 2007
	Häussler B, Höer A
	IGES Institut GmbH, Berlin, Germany

PHP31	IS PATENT PROTECTION CREATING OPPORTUNITY FOR INNOVATION ? - THE ALENDRONATE CASE IN BELGIUM
	Arickx F, Pierlet M, Soete E, VanHaeren E, Verplanken P, VanWilder P
	RIZIV National Health Insurance Agency, Brussels, Belgium

PHP32	COST-BENEFIT ANALYSIS OF PUBLIC HOSPITAL DEVELOPMENT
	Kalo Z¹, Lukovics M², Donkane Verebes E³, Sampar P⁴
	¹Eotvos Lorand University, Budapest, Hungary, ²Szeged University, Szeged, Hungary, ³Integra Zrt;, Budapest, Hungary, ⁴PricewaterhouseCoopers Ltd, Budapest, Hungary

PHP33	INFLUENCE OF MORBIDITY ON THE USE OF RESOURCES IN PRIMARY CARE: RETROSPECTIVE APPLICATION OF ACG AT A SPANISH INTERREGIONAL LEVEL
	Sicras-Mainar A¹, Navarro-Artieda R², Velasco S¹, Prados S³, Estelrich J¹
	¹Badalona Servicios Asistenciales, Barcelona, Spain, ²Hospital Germans Trias i Pujol, Barcelona, Spain, ³Instituto aragonés de ciencias de la Salud, Barcelona, Spain

PHP34	COSTS ASSOCIATED TO ADDITIONAL TEMPORAL SICK LEAVE DAYS IN THE IMSS
	Contreras-Hernandez I, Olvera-Gomez JL, Garduño-Espinosa J
	Social Security Mexican Institute, Mexico City, Mexico

PHP35	PHARMACEUTICAL EXPENDITURE IN GREECE 1980-2006
	Karampli E¹, Ollandezos M¹, Kousoulakou H², Tsiantou V¹, Athanasakis K¹, Kyriopoulos J¹
	¹National School of Public Health, Athens, Greece, ²Foundation for Economic and Industrial Research, Athens, Greece

PHP36	PERFORMANCE OF YOUR 5-STAR HOSPITALS
	Baser O
	University of Michigan and STATinMED Research, Ann Arbor, MI, USA

PHP37	HEALTH EXPENDITURES AND PERFORMANCE. THE ANÁLISIS OF THE FINANCIAL GAPS IN BUENOS AIRES PROVINCE
	Maceira DA¹, Kremer P²
	¹CIPPEC Foundation, Buenos Aires, Argentina, ²Center for the Implementation of Public Policies Towards Equity and Growth (CIPPEC), Ciudad Autónoma de Buenos Aires, Capital Federal, Argentina

PHP38	COST-EFFECTIVENESS OF PREVENTION: OPPORTUNITIES FOR PUBLIC HEALTH POLICY IN THE NETHERLANDS?
	Van den Berg M, van Gils P, De Wit GA, Schuit J
	National Institute for Public Health and the Environment, Bilthoven, Netherlands

PHP39	LINKING HOSPITAL ADMISSION DATA INTO PRIMARY CARE RECORDS WITHIN THE GENERAL PRACTICE RESEARCH DATABASE
	Williams TJ¹, Eaton S², Puri S¹, Van Staa TP¹
	¹Medicines and Healthcare Product Regulatory Agency, London, United Kingdom, ²Medicines and Healthcare Product Regulatory Agency, Raleigh, NC, USA

PHP40	INVESTIGATING THE PROMOTION OF HEALTH BEHAVIOR AND HEALTH-RELATED QUALITY OF LIFE BY APPLYING SELF-DETERMINATION THEORY: USING "EXERCISE" AS AN EXAMPLE
	Lin WL, Yao G
	National Taiwan University, Taipei, Taiwan

PHP41	ANALYSIS OF CLINICAL PHARMACISTS' INTERVENTIONS IN A UNIVERSITY TEACHING HOSPITAL IN OMAN
	Al Zadjali B¹, Al Zakwani I¹, Al Kindi M², Al Barram A³, Al Siyabi K³
	¹Sultan Qaboos University Hospital, Muscat, Oman, ²Sultan Qaboos University Hospial, MUSCAT, Oman, ³SULTAN QABOOS UNIVERSITY HOSPITAL, MUSCAT, Oman

PHP42	EVALUATION OF THE AFTERNOON OUTPATIENT CLINICS OPERATION AT THE UNIVERSITY HOSPITAL IN LARISA
	Geitona M¹, Androutsou L², Mpouki L³
	¹University of Thessaly, Volos, Greece, ²University of Thessaly, Athens, Greece, ³5th Regional Health Authority of Thessaly, Larisa, Greece

PHP43	GREEK HOSPITALS' SUPPLY CHAIN MANAGEMENT
	Perros G¹, Kalogeropoulou M², Tsantiris S¹, Tzonis P³
	¹Hellenic Association Of Pubic Health Doctors, Athens, Greece, ²Kapodistrian University of Athens, Athens, Greece, ³Hellenic Association Of Pubic Health Doctors, Athens, Attiki, Greece

PHP44	INEQUALITIES IN THE FINANCING OF DRUGS AMONG AUTONOMOUS REGIONS IN SPAIN
	Badia X, Vieta A
	IMS Health, Barcelona, Spain

PHP45	THE REIMBURSEMENT OF ORPHAN DRUGS ACROSS EUROPE
	Nixon F
	Heron Evidence Development Ltd, Letchworth Garden City, United Kingdom

PHP46	CATEGORISING RESEARCH: WHERE IS THE FOCUS?
	Samuels E, Plested M
	Heron Evidence Development Ltd, Letchworth Garden City, United Kingdom

HEALTH CARE USE & POLICY STUDIESHealth Care Research & Education
PHP47	ASSOCIATION BETWEEN HEALTH-RELATED QUALITY OF LIFE AND HEALTH SERVICE UTILIZATION AMONG PRIMARY CARE PATIENTS
	Chen T, Li L
	Zhejiang University, Hangzhou, China

PHP48	THE EFFECTS OF NICE HTA'S ON PRESCRIPTION VOLUME, AVERAGE RETAIL PRICE AND AVERAGE OUT-OF-POCKET COSTS OF DRUGS DEEMED MEDICALLY NECESSARY FOR MEDICARE PART D REIMBURSEMENT IN THE UNITED STATES
	Sepulveda B, Horowicz-Mehler N, Doyle JJ
	Quintiles Global Consulting, Hawthorne, NY, USA

HEALTH CARE USE & POLICY STUDIESHealth Technology Assessment Programs
PHP49	ANALYSIS OF FACTORS ASSOCIATED WITH REIMBURSEMENT DECISION MAKING IN HEALTH TECHNOLOGY ASSESSMENT AGENCIES (HTA)
	Bending MW¹, Kruger J¹, Hutton J¹, McGrath C²
	¹University of York, York, North Yorkshire, United Kingdom, ²Pfizer Inc, Surrey, United Kingdom

PHP50	UNIVERSAL STEPS IN PERFORMING EARLY-STAGE MEDICAL TECHNOLOGY ASSESSMENT
	O'Prinsen AC¹, Gaultney J², Redekop WK²
	¹Philips Research Asia, Shanghai, China, ²Erasmus Medical Center, Rotterdam, Netherlands

PHP51	OTHER HEALTH TECHNOLOGY ASSESSMENT GROUPS OPERATING IN ENGLAND; ITS NOT JUST NICE THAT NEEDS TO BE TAKEN INTO CONSIDERATION
	Way J¹, Mallinson M¹, Bridge JA²
	¹Double Helix Consulting, London, United Kingdom, ²Pfizer, Surrey, United Kingdom

PHP52	EVALUATION OF CURRENT ASSESSMENTS OF WORLDWIDE AGENCIES FOR HEALTH TECHNOLGY ASSESSMENT
	Wiebinga C, van Engen A, Andreykiv M
	Quintiles Consulting, Hoofddorp, Netherlands

HEALTH CARE USE & POLICY STUDIESPatient Registries & Post-Marketing Studies
PHP53	EXPANDING THE PHYSICIAN QUALITY REPORTING INITIATIVE (PQRI): MEASURES GROUPS AND REGISTRY-BASED REPORTING
	Pierce CA
	The Resource Group, Richfield, OH, USA

PHP54	ANTIBIOTICS CONSUMPTION IN THE REPUBLIC OF SERBIA IN 2004, 2005, 2006 AND 2007
	Radonjic V, Djukic L, Stefanovic D, Tesic D
	Medicines and Medical Devices Agency of Serbia, Belgrade, Serbia and Montenegro

HEALTH CARE USE & POLICY STUDIESPrescribing Behavior & Treatment Guidelines
PHP55	CHIRALTY AND HOSPITAL FORMULARY: A SECOND LIFE FOR A BLOCKBUSTER
	Vernaz-Hegi N¹, Girardin F¹, Muscionico D², Salomon JL², Bonnabry P¹
	¹Geneva University Hospitals, Geneva, Switzerland, ²OFAC, Geneva, Switzerland
PHP56	IMPACT OF ICU SEDATION PRACTICE ON PATIENT MORBIDITY, COST AND HOSPITAL RESOURCE USE: A SYSTEMATIC REVIEW
	Jackson D¹, Proudfoot CW², Knight CJ³, Cann K⁴, Lock K²
	¹GE Healthcare, Bucks, United Kingdom, ²Heron Evidence Development Ltd, Letchworth Garden City, United Kingdom, ³Heron Evidence Development Ltd, Letchworth, United Kingdom, ⁴Heron Evidence Development Ltd, Hertfordshire, United Kingdom
PHP57	INAPPROPRIATE SEDATION IN ICUS: EVIDENCE FROM THE LITERATURE
	Jackson D¹, Proudfoot CW², Knight CJ³, Cann K⁴, Lock K²
	¹GE Healthcare, Bucks, United Kingdom, ²Heron Evidence Development Ltd, Letchworth Garden City, United Kingdom, ³Heron Evidence Development Ltd, Letchworth, United Kingdom, ⁴Heron Evidence Development Ltd, Hertfordshire, United Kingdom

HEALTH CARE USE & POLICY STUDIESQuality of Care
PHP58	EVALUATING THE PERFORMANCE OF AN INNOVATIVE PUBLIC HEALTH INSURANCE: THE CASE OF A DECENTRALIZED PROVINCE IN ARGENTINA
	Maceira DA¹, Kremer P²
	¹CIPPEC Foundation, Buenos Aires, Argentina, ²Center for the Implementation of Public Policies Towards Equity and Growth (CIPPEC), Ciudad Autónoma de Buenos Aires, Capital Federal, Argentina

HEALTH CARE USE & POLICY STUDIESRegulation of Health Care Sector
PHP59	LABEL CLAIMS BASED ON PATIENT REPORTED OUTCOMES IN EMEA AND FDA APPROVALS SINCE 2000
	Scott J
	Mapi Values, Macclesfield, Cheshire, United Kingdom
PHP60	COMPARISON OF THE HEALTH ECONOMIC GUIDELINES OF THE CZECH REPUBLIC, HUNGARY, POLAND AND THE SLOVAK REPUBLIC
	Petříková A¹, Doležal T², Vašut K¹
	¹University of Veterinarian and Pharmaceutical Sciences Brno, Brno, Czech Republic, ²Charles University, Praha, Czech Republic

INDIVIDUAL'S HEALTH Clinical Outcomes Studies
PIH1	CHANGES IN PELVIC FLOOR MUSCLE STRENGTH, ITS DURATION AND ITS RELAXATION ABILITY DURING PREGNANCY
	Hock M¹, Kránicz J¹, Kivés Z¹, Kriszbacher I¹, Sebestyen A², Boncz I¹, Bódis J¹
	¹University of Pecs, Pecs, Hungary, ²National Health Insurance Fund Administration, Pecs, Hungary

PIH2	ONE DAY NATIONAL SURVEY ON PREVALENCE OF MALE SEXUAL DYSFUNCTION, AMONG MEN CONSULTING UROLOGISTS
	Droupy S¹, Giuliano F², Cuzin B³, Costa P⁴, Vicaut E⁵, Levrat F⁶
	¹CHU de Bicêtre, le Kremlin Bicêtre, France, ²AP-HP, hôpital Raymond Poincaré, Garches, France, ³Groupement Hospitalier E Herriot, Lyon, France, ⁴CHU Carémeau, Nîmes, France, ⁵Lariboisière St Louis, Hôpital F. Widal, Paris, France, ⁶Pfizer, Paris, France

PIH3	EPIDEMIOLOGICAL SURVEILLANCE OF CONGENITAL MALFORMATIONS IN 52,744 BIRTHS COLOMBIAN BETWEEN APRIL 2001 AND JANUARY 2008
	Zarante I, Fernandez N, Franco L
	Pontificia Universidad Javeriana, Bogota, Colombia

PIH4	WITHDRAWN



PIH5	INCIDENCE OF MAJOR MALFORMATIONS IN INFANTS FOLLOWING ANTIDEPRESSANT EXPOSURE IN PREGNANCY: RESULTS OF A LARGE PROSPECTIVE COHORT STUDY
	Einarson A¹, Choi J¹, Einarson TR², Koren G¹
	¹The Hospital for Sick Children, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada

INDIVIDUAL'S HEALTH Cost Studies
PIH6	SYSTEMATIC REVIEW OF ECONOMIC EVALUATION STUDIES IN OBSTETRICS, GYNAECOLOGY AND REPRODUCTIVE MEDICINE
	Vijgen SM, Opmeer BC, Mol B
	Academic Medical Centre, Amsterdam, Netherlands
PIH7	ECONOMIC ANALYSIS OF TREATMENT WITH IUI-COH VERSUS 6 MONTHS DELAY OF TREATMENT IN COUPLES WITH UNEXPLAINED SUBFERTILITY
	Mol B¹, Van Rumste M¹, Custers I¹, Steures P¹, Van der Steeg J¹, Hompes P², Eijckemans R³, Mochtar M¹, Bossuyt P¹, Van der Veen F¹
	¹Academic Medical Centre, Amsterdam, Netherlands, ²Vrije Universiteit, Amsterdam, Netherlands, ³Erasmus University, Rotterdam, Netherlands
PIH8	COST-EFFECTIVENESS OF PLANNED CAESAREAN SECTION VERSUS PLANNED VAGINAL DELIVERY IN BREECH-PRESENTATION PREGNANCIES AT TERM
	Vijgen SM, Opmeer BC, Mol BW
	Academic Medical Centre, Amsterdam, Netherlands
PIH9	COST-EFFECTIVENESS OF LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM (LNG-IUS) FOR THE TREATMENT OF DYSFUNCTIONAL UTERINE BLEEDING (DUB) IN SPAIN
	Lete I¹, Cristóbal I², Febrer L³, Crespo C⁴, Hernández FJ³, Arbat A³, Serrano D⁵, Brosa M⁶
	¹Hospital Santiago Apóstol, Vitoria, Álava, Spain, ²Hospital Sanitas La Zarzuela, Madrid, Madrid, Spain, ³Bayer HealthCare, SJD (Barcelona), Catalunya, Spain, ⁴Oblikue Consulting, Barcelona, Spain, ⁵Oblikue Consulting, Barcelona, Catalunya, Spain, ⁶Oblikue Consulting, Barcelona, SC, Spain
PIH10	THE COST EFFECTIVENESS OF SCHEDULED MAINTENANCE TREATMENT WITH INFLIXIMAB AMONG PAEDIATRIC PATIENTS WITH CROHN'S DISEASE IN SCOTLAND
	Punekar YS¹, Sunderland T², Morris J³
	¹Schering-Plough Ltd, Welwyn Garden City, Hertfordshire, United Kingdom, ²Sheffield University, Sheffield, United Kingdom, ³Schering-Plough, Welwyn Garden City, United Kingdom
PIH11	COST OF INSOMNIA IN PATIENTS OVER 54 YEARS IN SWEDEN
	Justo N, Jönsson L, Ekman M, Berg J
	i3 Innovus, Stockholm, Sweden
PIH12	INPATIENT LENGTH OF STAY AND TOTAL COSTS OF ILLNESSES OF PRESSING CONCERN FOR ASIAN-AMERICAN AND PACIFIC ISLANDER WOMEN IN THE UNITED STATES
	Candrilli SD¹, Davis KL², Balkrishnan R¹
	¹The Ohio State University, Columbus, OH, USA, ²RTI Health Solutions, Research Triangle Park, NC, USA
PIH13	ASSESSING THE INCREASED MATERNAL AND NEONATAL HEALTH CARE COSTS ASSOCIATED WITH PREECLAMPSIA
	Chawla A¹, White LA², Mitchell D³, Chang E², Gorin B², Woelkers D⁴, Vargo J⁵, Rahman M⁵
	¹Analysis Group, Menlo Park, CA, USA, ²Analysis Group, Boston, MA, USA, ³Analysis Group, Montreal, QC, Canada, ⁴University of California, San Diego, San Diego, CA, USA, ⁵Ortho Clinical Diagnostics, Raritan, NJ, USA
PIH14	COSTS AND OUTCOMES ASSOCIATED WITH IN VITRO FERTILISATION (IVF) OR INTRACYTOPLASMIC SPERM INJECTION (ICSI) USING RECOMBINANT FOLLICLE STIMULATING HORMONE (RFSH)
	Holman AJ¹, Irwin DE², Ledger W³, Anderson P¹, Wiebinga CJ⁴, Lloyd AC¹
	¹IMS Health, London, United Kingdom, ²University of North Carolina, Chapel Hill, NC, USA, ³University of Sheffield, Sheffield, United Kingdom, ⁴N.V. Organon, Oss, Netherlands

INDIVIDUAL'S HEALTH Patient-Reported Outcomes Studies
PIH15	HEALTH-RELATED QUALITY OF LIFE IN ADOLESCENTS WITH THE PRADER-WILLI SYNDROME
	Sintonen H¹, Viita AM², Leinonen ES², Apajasalo M³, Sipilä I⁴
	¹University of Helsinki, Helsinki, Finland, ²Oy Eli Lilly Finland Ab, Vantaa, Finland, ³Hospital for Children and Adolescents, Helsinki, Finland, ⁴Mehiläinen Medical Center, Helsinki, Finland
PIH16	PSYCHOMETRIC PERFORMANCE OF THE CHILDREN'S DERMATOLOGY QUALITY OF LIFE INDEX
	Malhan S¹, Oksuz E¹, Tulunay FC²
	¹Baskent University, Ankara, Turkey, ²Ankara University Medical School, Ankara, Turkey
PIH17	TURKISH CULTURAL ADAPTATION AND VALIDATION OF THE MENOPAUSE-SPECIFIC QUALITY OF LIFE QUESTIONNAIRE
	Malhan S¹, Oksuz E¹, Tulunay FC²
	¹Baskent University, Ankara, Turkey, ²Ankara University Medical School, Ankara, Turkey
PIH18	RELIABILITY, AND VALIDITY OF THE FATIGUE SYMPTOM INVENTORY
	Oksuz E¹, Malhan S¹, Tulunay FC²
	¹Baskent University, Ankara, Turkey, ²Ankara University Medical School, Ankara, Turkey
PIH19	THE ASSOCIATION OF BODY MASS INDEX ON HEALTH RELATED QUALITY OF LIFE IN THE GENERAL ADULT POPULATION IN ENGLAND
	Søltoft F¹, Hammer M², Kragh N²
	¹University of Copenhagen, Frederiksberg C, Denmark, ²Novo Nordisk A/S, Bagsværd, Denmark
PIH20	WEIGHT-RELATED MORBIDITY AND FAMILY DISRUPTION FOLLOWING PEDIATRIC EMERGENCY DEPARTMENT TREATMENT (PED) OF ACUTE MINOR INJURY
	Hainsworth KR¹, Drendel AL¹, Stevens MW²
	¹Medical College of Wisconsin, Milwaukee, WI, USA, ²Medical College of Wisconsin; Children's Hospital of Wisconsin, Milwaukee, WI, USA
PIH21	EFFICACY OF TREATMENT AND PATIENT SATISFACTION IN TREATMENT OF CLIMACTERIC DISORDERS WITH SOY ISOFLAVONES: FRENCH APPROCH
	Mares P¹, Bruel P², Boussetta S³, Taieb C⁴
	¹Gynecologist Dpt, Nimes, France, ²Plantes et Médecines, Castres, France, ³Pierre Fabre, Boulogne Billancourt, France, ⁴Pierre Fabre, Boulogne, France

INDIVIDUAL'S HEALTH Health Care Use & Policy Studies
PIH22	PRICE-ELASTICITY OF DEMAND FOR INFERTILITY SERVICES IN GERMANY
	Connolly M¹, Ledger WL²
	¹Global Market Access Solutions, St Prex, Switzerland, ²University of Sheffield, Sheffield, United Kingdom

PIH23	MEDICATION COSTS IN ELDERLY PATIENTS
	Mendes Z¹, Guedes S², Batel Marques F³, Miranda A²
	¹Cefar, Lisbon, Portugal, ²Infosaude, Lisbon, Portugal, ³University of Coimbra, Lisbon, Portugal

PIH24	ASSESSMENT OF CURRENT CLINICAL PRACTICE AMONG PHYSICIANS AND SEX THERAPISTS REGARDING ERECTILE DYSFUNCTION (ED) TREATMENT INITIATION WITH PHOSPHODIESTERASE-5 INHIBITORS (PDE5I)
	Schnetzler G¹, Marfatia A², Symonds T³, Chambers R², Muniain J⁴
	¹Pfizer International Operations, Paris, France, ²Pfizer Inc, New York, NY, USA, ³Pfizer Global Research & Development, Sandwich, United Kingdom, ⁴Surfernet, Rutherford, NJ, USA

INFECTION Clinical Outcomes Studies

PIN1	A BAYESIAN META-ANALYSIS OF THE EFFICACY OF SIX ANTIMICROBIAL AGENTS FOR CONFIRMED STAPHYLOCOCCUS AUREUS COMPLICATED SKIN AND SOFT-TISSUE INFECTIONS (CSSTIS)
	Logman JFS¹, Treur MJ¹, Verheggen BG¹, Heeg BMS¹, Stephens J², Spiesser J³, Simoneau D³, Haider S⁴, Nathwani D⁵, Van Hout BA¹
	¹Pharmerit Europe, Rotterdam, Netherlands, ²Pharmerit North America LLC, Bethesda, MD, USA, ³Pfizer PIO, Paris Cedex 14, France, ⁴Pfizer Inc, Groton, CT, USA, ⁵Ninewells Hospital & Medical School, Dundee, United Kingdom

PIN2	ASSESSING ANTIMICROBIAL SUCCESS RATES IN THE TREATMENT OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) COMPLICATED SKIN AND SOFT TISSUE INFECTIONS (CSSTI): A BAYESIAN META-ANALYSIS
	Logman JFS¹, Treur MJ¹, Verheggen BG¹, Heeg BMS¹, Stephens JM², Haider S³, Cappelleri J³, Nathwani D⁴, Tice A⁵, Van Hout BA¹
	¹Pharmerit Europe, Rotterdam, Netherlands, ²Pharmerit North America LLC, Bethesda, MD, USA, ³Pfizer Inc, Groton, CT, USA, ⁴Ninewells Hospital & Medical School, Dundee, United Kingdom, ⁵University of Hawaii, Honolulu, HI, USA

PIN3	A SIMULATION-BASED APPROACH TO MODELING THE EFFECTS OF INTERVENTION STRATEGIES ON THE SPREAD OF MENINGOCOCCAL MENINGITIS
	Smolen HJ¹, Einterz RM²
	¹Medical Decision Modeling Inc, Indianapolis, IN, USA, ²Indiana University, Indianapolis, IN, USA

PIN4	A MARKOV MODEL TO ESTIMATE THE IMPACT ON MORBIDITY AND MORTALITY IN PATIENTS WITH CHRONIC HEPATITIS C (CHC) AND NORMAL TRANSAMINASES (ALT-N) TREATED WITH PEGYLATED BITHERAPY
	Deuffic-Burban S¹, Moser A², Cartier V², Deltenre P³, Canva-Delcambre V³, Dharancy S³, Louvet A³, Roudot-Thoraval F⁴, Mathurin P³
	¹INSERM U795, Lille, France, ²Roche Pharma, Neuilly sur Seine Cedex, France, ³CHRU de Lille, Lille Cedex, France, ⁴Hopital Henri-Mondor, Creteil, France

PIN5	IMPACT OF MASS VACCINATION WITH MMRV VERSUS MMR IN FRANCE ON THE EPIDEMIOLOGY OF VARICELLA AND HERPES ZOSTER, USING A DYNAMIC TRANSMISSION MODEL
	Vissers D¹, Ouwens M¹, Littlewood K¹, Jansen JP²
	¹Mapi Values, Houten, Netherlands, ²Mapi Values, Boston, MA, USA

PIN6	AN OBSERVATIONAL HEALTH ECONOMIC ANALYSIS OF THE COMBINED THERAPY WITH PEGINTERFERON ALPHA-2A (PEGASYS®) AND RIBAVIRIN IN PATIENTS WITH CHRONIC C HEPATITIS (CHC) IN A REAL LIFE SETTING
	Fagnani F¹, Moser A², Pinta A², Hayem C², Bourlière M³, Ouzan D⁴, Deffoel M⁵, Marcellin P⁶, Vray M⁷
	¹Cemka-Eval, Bourg-la-Reine, France, ²Roche Pharma, Neuilly sur Seine cedex, France, ³Saint Joseph Hospital, Marseille, France, ⁴Institut, Saint-Laurent-du-Var, France, ⁵CHU Strasbourg, Strasbourg, France, ⁶Hôpital Beaujon, Clichy, France, ⁷Institut Pasteur, Paris, France

PIN7	PHARMACOGENOMICS: RELEVANCE AND APPLICABILITY IN POST-GENOMIC ERA (HIV-THERAPY)
	Chawla A, Kumar R, Aneja G, Bhanderi M, Sehgal M
	Heron Health Private Ltd, Chandigarh, India

PIN8	PATIENT FLOW PATHWAY FOR PATIENTS ADMITTED TO CRITICAL CARE UNITS WITH A SEVERE BACTERIAL INFECTION IN ENGLAND
	Das R, Edwards SJ, Emmas C
	AstraZeneca UK Ltd, Luton, United Kingdom

INFECTION Cost Studies
PIN9	BUDGET IMPACT ANALYSIS OF INTRODUCING ROUTINE VACCINATION WITH A QUADRIVALENT HPV-VACCINE IN NORWAY
	Kristensen FKO, Sverre JM, Nyhus K
	PharmEcon, Asker, Akershus, Norway

PIN10	THE ECONOMIC IMPACT OF LOWER HIV PREVALENCE ESTIMATES
	Ho J, Becker RV
	Dymaxium Inc, Toronto, ON, Canada

PIN11	COST-EFFECTIVENESS OF QUADRIVALENT HPV VACCINATION IN FINLAND
	Väänänen JJP¹, Herse F¹, Korkeamäki J², Parvinen PMT¹, Remy V³
	¹Nordic Healthcare Group, Helsinki, Finland, ²Sanofi Pasteur MSD Oy, Helsinki, Finland, ³Sanofi Pasteur MSD, Lyon, France

PIN12	COST-EFFECTIVENESS OF CERVARIX^TM, A PROPHYLACTIC CERVICAL CANCER VACCINE, IN SPAIN
	Gauthier A¹, Moore L¹, Martín-Escudero V², Peterson C¹, Pérez I², de Sanjosé S³
	¹i3 Innovus, Uxbridge, United Kingdom, ²GlaxoSmithKline, Madrid, Spain, ³ICO-CIBERESP, Barcelona, Spain

PIN13	ECONOMIC ANALYSIS OF MICAFUNGIN VERSUS LIPOSOMAL AMPHOTERICIN B FOR TREATMENT OF CANDIDAEMIA AND INVASIVE CANDIDIASIS IN ITALY
	Viale P¹, Sidhu M², van Engen A³, Schoeman O³
	¹Policlinico Universitario di Udine, Udine, Italy, ²Astellas Pharma Europe Ltd, Staines, United Kingdom, ³Quintiles Consulting, Hoofddorp, Netherlands

PIN14	USING A DECISION SIMULATION MODEL TO EVALUATE THE COST-EFFECTIVENESS OF THE TREATMENT OF NUCLEOSIDE-NAÏVE HBE-ANTIGEN NEGATIVE CHB PATIENTS IN ITALY WITH ENTECAVIR AND TENOFOVIR
	Zammit DC¹, Yuan Y², Intorcia M³, Hay JW⁴
	¹Bristol-Myers Squibb, Braine l-A'lleud, Belgium, ²Bristol-Myers Squibb, Princeton, NJ, USA, ³Bristol-Myers Squibb, Rome, Italy, ⁴University of Southern California, Los Angeles, CA, USA

PIN15	COST-EFFECTIVENESS OF PALIVIZUMAB IN THE PROPHYLAXIS OF SEVERE BRONCHIOLITIS CAUSED BY RSV: RESULTS OF A DECISION MODEL WITH LOCAL DATA
	García-Altés A¹, Paladio N², Pons J², Tebé C²
	¹Fundación Instituto de Investigación en Servicios de Salud, Barcelona, Spain, ²Catalan Agency for Health Technology Assessment and Research, Barcelona, Spain

PIN16	COST-EFFECTIVENESS OF A PROPHYLACTIC HUMAN PAPILLOMA VIRUS 16/18 VACCINE FOR 12-YEAR-OLD DUTCH GIRLS
	Westra TA¹, Rogoza R², Ferko N², Tamminga JJ³, Drummond MF⁴, Wilschut JC¹, Postma MJ⁵
	¹University Medical Centre Groningen, Groningen, Netherlands, ²i3 Innovus, Burlington, ON, Canada, ³GlaxoSmithKline BV, Zeist, Netherlands, ⁴University of York, York, Heslington, United Kingdom, ⁵University of Groningen, Groningen, Netherlands

PIN17	COST-EFFECTIVENESS OF MASS VACCINATION FOR VARICELLA IN FRANCE WITH MMRV VERSUS MMR
	Littlewood K¹, Vissers D¹, Ouwens M¹, Jansen JP², Postma M³
	¹Mapi Values, Houten, Netherlands, ²Mapi Values, Boston, MA, Netherlands, ³University of Groningen, Groningen, Netherlands

PIN18	ANALYSIS OF COST-EFFECTIVENESS OF ITRACONAZOLE IN THE TREATMENT OF INVASIVE ASPERGILLOSIS IN TURKISH SETTING
	Kanbur B, Sarioz F, Tatar F
	Janssen-Cilag, Istanbul, Turkey

PIN19	PHARMACOECONOMIC EVALUATION OF PARENTERAL ITRACONAZOLE USE IN THE PROPHYLAXIS OF INVASIVE FUNGAL INFECTIONS IN TURKISH SETTING
	Kanbur B, Sarioz F, Tatar F
	Janssen-Cilag, Istanbul, Turkey

PIN20	COST-EFFECTIVENESS OF SURGICAL INTERVENTION FOR THERAPY-INDUCED FACIAL LIPOATROPHY IN HIV-INFECTED PATIENTS
	Massella M¹, Scalone L², Ivanovic J³, Narciso P³, Bellagamba R³, Fragola V¹, Tozzi V³
	¹Istituto Superiore di Sanità, Rome, Italy, ²Università degli Studi di Milano, Milan, Italy, ³INMI L. Spallanzani, Rome, Italy

PIN21	ECONOMICAL EVALUATION OF ETRAVIRINE IN TREATMENT-EXPERIENCED HIV-1-INFECTED PATIENTS BASED ON DUET TRIALS
	Avxentyeva M, Vorobyev P
	Moscow Medical Academy named after I.M.Sechenov, Moscow, Russia

PIN22	COST-EFFECTIVENESS ANALYSIS OF VACCINATION AGAINST ROTAVIRUS WITH RIX4414 IN FRANCE
	Standaert BA¹, Parez N², Tehard B³, Colin X⁴, Detournay B⁵
	¹GlaxoSmithKline Biologicals, Rixensart, Belgium, ²Assistance Publique, Hôpital Armand Trousseau, Paris, France, ³GlaxoSmithKline, Marly-le-Roi, France, ⁴Cemka-Eval, Bourg-La-Reine, France, ⁵CEMKA-EVAL, Bourg-la-Reine, France

PIN23	COST-EFFECTIVENESS ANALYSIS OF 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN TAIWAN: TRANSMISSION DYNAMIC MODEL-BASED EVALUATIONS
	Fann CS¹, Wu D², Huang YC³, Chang CJ⁴
	¹Academia Sinica, Taipei, Taiwan, ²National Yang-Ming University, Taipei, Taiwan, ³Chang-Gung Memorial Hospital, Taoyuan, Taiwan, ⁴Chang Gung University, Taoyuan, Taiwan

PIN55	COST-EFFECTIVENESS OF DARUNAVIR/RITONAVIR 600/100MG BID IN TREATMENT-EXPERIENCED, LPV/R-NAÏVE, PI-RESISTANT, HIV-INFECTED ADULTS IN THE UNITED KINGDOM, BELGIUM, ITALY AND SWEDEN
	Moeremans K1, Hemmett LC2, Hjelmgren J3, Allegri G4, Smets E5
	1IMS Health HEOR, Brussels, Belgium, 2Tibotec, a division of Janssen-Cilag Ltd, Buckinghamshire, UK, 3Janssen-Cilag AB, Sollentuna, Sweden, 4Tibotec, a division of Janssen-Cilag S.p.A, Cologno Monzese - Milano b, Italy, 5Johnson & Johnson Pharmaceutical Services, Mechelen, Belgium

PIN24	ECONOMIC AND CLINICAL IMPACT OF IMPLEMENTATION OF AN ACELLULAR PERTUSSIS VACCINE IN CANADA
	Iskedjian M¹, Walker J¹, De Serres G², Einarson TR¹
	¹PharmIdeas Research and Consulting Inc, Oakville, ON, Canada, ²Université Laval, Québec, QC, Canada

PIN25	COST-EFFECTIVENESS OF 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV) INCLUDING HERD PROTECTION IN TURKEY
	Türel Ö¹, McIntosh D², Bakir M¹
	¹Marmara University, Istanbul, Turkey, ²Wyeth Europe, Berkshire, United Kingdom

PIN26	COST-EFFECTIVENESS OF TREATMENT WITH PEGASYS/COPEGUS IN HIV/HCV CO-INFECTED PATIENTS IN PORTUGAL
	Macedo A¹, Monteiro I², Nunes S¹, Farinha S², Pereira C²
	¹KeyPoint, Consultoria Científica Lda, Lisbon, Portugal, ²Roche Farmacêutica Química, Lda, Amadora, Portugal

PIN27	COST-EFFECTIVENESS ANALYSIS OF CASPOFUNGIN VERSUS AMPHOTERICIN B, VORICONAZOLE, AND ANIDULAFUNGIN IN THE TREATMENT OF INVASIVE CANDIDIASIS
	Verheggen BG¹, Heeg BMS¹, Vos CBJ², Van Hout BA¹
	¹Pharmerit Europe, Rotterdam, Netherlands, ²Merck Sharp & Dohme BV, Haarlem, Netherlands

PIN28	USE OF PEGINTERFERON ALFA-2B IN CHRONIC HEPATITIS C PATIENTS FAILING PRIOR THERAPY: A COST-EFFECTIVENESS ANALYSIS
	O'Sullivan AK¹, Buti M², Delong K¹, Prasad M³, Sabater FJ⁴, Esteban R², Weinstein MC⁵
	¹i3 Innovus, Medford, MA, USA, ²Hospital General Universitario Valle de Hebrón, Barcelona, Spain, ³Schering-Plough Corporation, Kenilworth, NJ, USA, ⁴Schering-Plough S.A, Alcobendas, Spain, ⁵Harvard University, Boston, MA, USA

PIN29	EFFECTIVENESS AND COST-EFFECTIVENESS OF HEPATITIS C SCREENING – A SYSTEMATIC REVIEW
	Sroczynski G¹, Esteban E¹, Conrads-Frank A¹, Schwarzer R¹, Mühlberger N¹, Wright DR², Zeuzem S³, Siebert U¹
	¹UMIT - University for Health Sciences, Medical Informatics and Technology, Hall, Tirol, Austria, ²Harvard School of Public Health, Boston, MA, USA, ³Johann Wolfgang Goethe-University, Frankfurt a.M, Germany

PIN30	COST-EFFECTIVENESS ANALYSIS OF DROTRECOGIN ALFA (ACTIVATED; DAA) AS A TREATMENT FOR SEVERE SEPSIS WITH MULTIPLE ORGAN FAILURE (MOF) IN POLAND
	Kuzma J¹, Kawalec P¹, Bochenski P²
	¹Centrum HTA, Krakow, Poland, ²Ely Lilly, Warsaw, Poland

PIN31	COST-MINIMIZATION ANALYSIS OF ETRAVIRINE AND RALTEGRAVIR, TWO NEW HIV TREATMENTS FOR TREATMENT-EXPERIENCED PATIENTS
	Martin SC
	Johnson & Johnson Pharmaceutical Services, LLC, Mechelen, Belgium

PIN32	COSTS OF INTERMITTENT VERSUS CONTINUOUS ANTIRETROVIRAL THERAPY IN PATIENTS WITH CONTROLLED HIV INFECTION. A SUBSTUDY OF THE ANRS 106 WINDOW TRIAL
	Charreau I¹, Jeanblanc G², Tangre P¹, Marchou B³, Aboulker JP¹, Molina JM⁴, Durand-Zaleski I²
	¹Paul Brousse Hospital, Villejuif, France, ²Henri Mondor Hospital, Créteil, France, ³Purpan Hospital, Toulouse, France, ⁴Hôpitaux de Paris, Paris, France

PIN33	COST-MINIMIZATION ANALYSIS OF DAPTOMYCIN FOR MRSA SKIN AND SOFT TISSUES INFECTIONS IN BRAZILIAN PRIVATE SECTOR
	Bueno RLP¹, Prismich G², Suzuki C²
	¹FEI, São Paulo, Brazil, ²Novartis Biociências S/A, São Paulo, Brazil

PIN34	COMPARISON OF GENERIC AND BRAND NAME ANTIBIOTIC USAGE IN TURKEY
	Malhan S¹, Oksuz E¹, Tulunay FC²
	¹Baskent University, Ankara, Turkey, ²Ankara University Medical School, Ankara, Turkey

PIN35	HEALTH ECONOMIC ASSESSMENT OF A PRE-PANDEMIC INFLUENZA VACCINE FOR GERMANY
	Postma MJ¹, Williams P², Neurohr C³, Welte R³
	¹University of Groningen, Groningen, Netherlands, ²Navitas BioPharma Consulting, Buckinghamshire, United Kingdom, ³GlaxoSmithKline, Munich, Germany

PIN36	SOCIO-ECONOMIC IMPACT OF AVIAN INFLUENZA IN SOUTH-EAST ASIA AND NEIGHBOURING HIGH RISK COUNTRIES
	Arora M, Srivastava K, Siddiqui MK, Verma J, Ahuja M, Sharma S
	Heron Health Private Ltd, Chandigarh, India

PIN37	GENITAL WARTS IN ITALY: A COST OF ILLNESS ANALYSIS
	Bamfi F¹, Marocco A¹, Capri S², Sideri M³
	¹GlaxoSmithKline Spa, Verona, Italy, ²Cattaneo-LIUC University, Castellanza, (Varese), Italy, ³European Institute of Oncology, Milano, Italy

PIN38	THE ECONOMIC BURDEN OF HCV AND HBV CO-INFECTION: EVIDENCE FROM UNITED STATES MANAGED CARE DATA
	Mitra D¹, Davis KL¹, Medjedovic J², Beam C³, Rustgi V⁴
	¹RTI Health Solutions, Research Triangle Park, NC, USA, ²Novartis Pharma AG, Basel, Switzerland, ³Human Genome Sciences, Inc, Rockville, MD, USA, ⁴Georgetown University Medical Center, Fairfax, VA, USA

PIN39	INPATIENT COSTS AND OUTCOMES ASSOCIATED WITH HEPATITIS C, HUMAN IMMUNODEFICIENCY VIRUS, AND CO-INFECTION WITH BOTH IN THE UNITED STATES
	Mitra D, Candrilli SD
	RTI Health Solutions, Research Triangle Park, NC, USA

PIN40	MANAGEMENT AND COST ASSOCIATED WITH NON-PERMANENT CATHETER-RELATED BACTERAEMIA CAUSED BY MICROORGANISMS GRAM-POSITIVES IN SPANISH HOSPITALS SETTINGS
	Ruíz-Antorán B¹, Hernández-Novoa B², Galvez-Mújica M², De-Pablo-López I², Sánchez M³, Mazarrasa C³, Alonso M⁴, Castillo J⁵, Martí B⁶, Soto J⁶
	¹Hospital Universitario Puerta de Hierro, Madrid, Spain, ²Hospital Ramón y Cajal, Madrid, Spain, ³Hospital Universitario “Marqués de Valdecilla”, Santander, Spain, ⁴Hospital de la Santa Creu I Sant Pau, Barcelona, Spain, ⁵Hospital Universitario “Virgen del Rocio”, Sevilla, Spain, ⁶Health Outcomes Research, Pfizer, Spain

PIN41	DEVELOPING AN ECONOMIC MODEL OF GRAM+ COMPLICATED SKIN AND SOFT TISSUE INFECTIONS (CSSTI) FOR INPATIENT AND OUTPATIENT TREATMENT SETTINGS
	Stephens JM¹, Treur MJ², Heeg BMS², Haider S³, Nathwani D⁴, Tice A⁵
	¹PharMerit North America LLC, Bethesda, MD, USA, ²Pharmerit Europe, Rotterdam, Netherlands, ³Pfizer Inc, New London, CT, USA, ⁴Ninewells Hospital & Medical School, Dundee, United Kingdom, ⁵Infections Limited Hawaii, Honolulu, HI, USA

PIN42	DIRECT MEDICAL COSTS AND PRODUCTIVITY LOSS ASSOCIATED WITH VENOUS LEG ULCER
	Chen S¹, Schafer V¹, Ottino JA¹, Bharmal M², Gemmen E², Choe Y¹
	¹ConvaTec, Skillman, NJ, USA, ²Quintiles Inc, Falls Church, VA, USA

IN4	ACHIEVING SUSTAINED VIROLOGIC RESPONSE WITH CHRONIC HEPATITIS C TREATMENT IS ASSOCIATED WITH IMMEDIATE HEALTH CARE UTILIZATION BENEFITS IN EUROPE
	Zhang H¹, Narayanan S²
	¹Johnson & Johnson Pharmaceutical Services, LLC, Raritan, NJ, USA, ²TNS Healthcare, New York, NY, USA

PIN43	DIFFERENCE IN HEALTHCARE UTILIZATION IN EUROPE BETWEEN TREATMENT-NAÏVE PATIENTS WITH CHRONIC HEPATITIS C AND PATIENTS WHO FAILED PRIOR THERAPY
	Zhang H¹, Narayanan S²
	¹Johnson & Johnson Pharmaceutical Services, LLC, Raritan, NJ, USA, ²TNS Healthcare, New York, NY, USA

INFECTIONPatient-Reported Outcomes Studies
PIN45	IMPACT OF PATIENT-HEALTH CARE PROVIDER COMMUNICATION: THE HIV/AIDS PATIENTS' PERSPECTIVES
	Layton MR¹, Kerr SJ², Chetchotisakd P³
	¹Khon Kaen University, Khon Kaen, Thailand, ²University of New South Wales, Sydney, New South Wales, Australia, ³Khon Kaen University, Khon Kaen, Khon Kaen, Thailand

PIN46	HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITH VENOUS LEG ULCER
	Chen S¹, Schafer V¹, Ottino JA¹, Bharmal M², Gemmen E², Choe Y¹
	¹ConvaTec, Skillman, NJ, USA, ²Quintiles Inc, Falls Church, VA, USA

PIN47	VALIDATION OF THE SINONASAL OUTCOME TEST-16 (SNOT-16) IN PATIENTS WITH ACUTE BACTERIAL SINUSITIS
	Lloyd A¹, Uhl-Hochgraber K², Piccirillo JF³
	¹Oxford Outcomes Ltd, Oxford, United Kingdom, ²Bayer Schering Pharma, Berlin, Germany, ³Washington University School of Medicine, St. Louis, MO, USA

PIN48	VALIDATION OF THE ACTIVITY IMPAIRMENT ASSESSMENT IN PATIENTS WITH ACUTE BACTERIAL SINUSITIS
	Lloyd A¹, Uhl-Hochgraber K², Keating K³
	¹Oxford Outcomes Ltd, Oxford, United Kingdom, ²Bayer Schering Pharma, Berlin, Germany, ³Bayer HealthCare Pharmaceuticals, West Haven, CT, USA

PIN49	INTERNATIONAL DEVELOPEMENT OF A NEW HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRE SPECIFIC TO HIV/AIDS – PROQOL HIV STUDY
	Duracinsky M¹, Acquadro C², Berzins B³, Hermann S⁴, Le Coeur S⁵, Fournier I⁶, Diouf A⁷, Kohli R⁸, Chassany O⁹
	¹Centre Hospitalier Universitaire de Bicetre, Le Kremlin-Bicetre, France, ²AP HP, Paris, France, ³Northwestern University, Chicago, Chicago, IL, USA, ⁴Royal Perth Hospital, Perth, Australia, ⁵Institut National d'Etudes Démographiques (INED), Chiang Mai, Thailand, ⁶Institut Pasteur, Phnom Penh, Cambodia, ⁷Centre de Recherche Clinique de Fann (CRCFP), Dakar, Senegal, ⁸National AIDS Research Institute, Pune, India, ⁹Assistance Publique - Hopitaux de Paris, Paris, France
INFECTIONHealth Care Use & Policy Studies
PIN50	A REVIEW OF THE FACTORS AFFECTING PUBLIC FUNDING OF VACCINES
	De Abreu Lourenco R, Strizek A
	Covance, North Ryde, New South Wales, Australia

PIN51	EVALUATION OF SEPSIS MANAGEMENT AND OUTCOMES AT A LARGE INNER-CITY ACADEMIC MEDICAL CENTER IN THE SURVIVING SEPSIS CAMPAIGN ERA
	Ohuabunwo CJ¹, Fotzeu C¹, Heisler M², VanDenBerg C³
	¹Morehouse School of Medicine, Atlanta, GA, USA, ²Emory UNiversity, Atlanta, GA, USA, ³Grady Health System, Atlanta, GA, USA

PIN52	UTILIZATION ANALYSIS AND IMPACT OF ANTIBACTERIAL AGENTS IN TWO LEADING UNIVERSITY HOSPITALS IN NEIGHBORING COUNTRIES WITH DIFFERENT GDP AND HEALTH CARE SYSTEM
	Francetic I¹, Gavrankapetanovic F², Begovic B², Bielen L³, Bolanca S⁴
	¹University Hospital Center Zagreb, Zagreb, Croatia, ²Clinical Center University of Sarajevo, Sarajevo, Bosnia, ³Medical School University of Zagreb, Zagreb, Croatia, ⁴Pfizer Croatia, Zagreb, Croatia

PIN53	PHARMACY-IMPLEMENTED GUIDELINES ON SWITCHING FROM INTRAVENOUS TO ORAL ANTIBIOTICS : A PROSPECTIVE STUDY IN A TEACHING HOSPITAL
	Briquet C¹, D'Hoore W², Bisot-Locard S³, Simon A¹, Tilleul P³
	¹Cliniques Universitaires Saint Luc, Brussels, Belgium, ²Université Catholique de Louvain (UCL), Brussels, Belgium, ³Université Paris Descartes, Paris cedex 12, France
INFECTIONConceptual Papers & Research on Methods
PIN54	ADAPTATION & CALIBRATION OF A UK MODEL OF MENINGOCOCCAL DISEASE TO THE US SETTING
	Aballéa S¹, McGarry LJ², Taylor DC², Hill G², Pawar V², Clements KM², Thompson D²
	¹i3 Innovus, Uxbridge, Middlesex, United Kingdom, ²i3 Innovus, Medford, MA, USA

RESPIRATORY-RELATED DISORDERSClinical Outcome Studies
PRS1	SMOKING, ASTHMA AND COPD IN ADULTS: A TOO FREQUENT RELATION
	Sicras A¹, Navarro-Artieda R²
	¹Badalona Servicios Asistenciales, Barcelona, Spain, ²Hospital Germans Trias i Pujol, Barcelona, Spain

PRS2	RELATIVE EFFECTIVENESS OF INHALED CORTICOSTEROIDS AND LEUKOTRIENE-RECEPTOR ANTAGONISTS TO PREVENT MODERATE-TO-SEVERE EXACERBATIONS AMONG ASTHMATIC CHILDREN
	Blais L¹, Kettani FZ¹, Lemière C², Beauchesne MF¹, Perreault S¹, Elftouh N¹
	¹Université de Montréal, Montreal, QC, Canada, ²Hôpital du Sacré-Coeur de Montréal, Montreal, QC, Canada

PRS3	PREVALENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE FROM ADMINISTRATIVE HEATH SERVICES DATABASES
	Citarella A, Menditto E, Cammarota S, De Portu S, Riegler S, Mantovani LG
	University of Naples, Federico II, Naples, Italy

PRS4	SUB-ACUTE LACK OF ASTHMA CONTROL AS A PREDICTOR OF ASTHMA EXACERBATION IN A MANAGED CARE POPULATION
	Stephenson JJ¹, Quimbo RA¹, Dai D¹, Gutierrez B²
	¹HealthCore Inc, Wilmington, DE, USA, ²AstraZeneca, Wilmington, DE, USA

PRS5	ESTABLISHING THE INCIDENCE AND PREVALENCE OF MULTIPLE ATOPIC CONDITIONS IN UK: COHORT STUDY USING THE GENERAL PRACTICE RESEARCH DATABASE
	Punekar YS¹, Gibbons CJ¹, Sheikh A²
	¹Schering-Plough Ltd, Welwyn Garden City, United Kingdom, ²University of Edinburgh, Edinburgh, United Kingdom

PRS6	WITHDRAWN

RESPIRATORY-RELATED DISORDERSConsumer Role in Health Care
PRS7	THE TREATMENT OF MODERATE TO SEVERE PERSISTENT ASTHMA IN SELECTED AUTONOMOUS COMMUNITIES IN SPAIN: AN ECOMIC MODEL TO ESTIMATE BUDGET IMPACT CONSEQUENCES OF INTRODUCING BECLOMETHASONE/FORMOTEROL
	Darba J¹, Restovic G²
	¹Universitat de Barcelona, Barcelona, Spain, ²BCN Health Economics & Outcomes Research SL, Barcelona, Spain

PRS9	COST-EFFECTIVENESS MODEL OF MOXIFLOXACIN IN ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS (AECB) IN GERMANY INCLUDING THE EFFECTS OF RESISTANCE
	Cure S¹, Quilici S¹, Martin M¹, Evers T², Schaberg T³, Mitfessel H⁴
	¹i3 Innovus, Uxbridge, Middlesex, United Kingdom, ²Bayer Schering Pharma, Wuppertal, Germany, ³Lungenklinik Unterstedt - Zentrum für Pneumologie, Rotenburg(Wümme), Germany, ⁴Private practice, Remscheid, Germany

PRS10	WITHDRAWN



PRS11	COST-EFFECTIVENESS OF INCREASING MAINTENANCE DOSES WITH BUDESONIDE/FORMOTEROL MAINTENANCE + RELIEVER THERAPY
	Kuna P¹, Aubier M², Buhl R³
	¹Barlicki University Hospital, Medical University of Lodz, Lodz, Poland, ²Hôpital Bichat Claude Bernard, Paris, France, ³Mainz University Hospital, Mainz, Germany

PRS12	COST-EFFECTIVENESS ANALYSIS OF SYMBICORT SMART® VERSUS FIXED COMBINATION TREATMENTS IN FINLAND
	Tamminen K¹, Laine J¹, Soini EJ², Martikainen JA², Kankaanranta H³
	¹AstraZeneca, Espoo, Finland, ²ESiOR Oy, Kuopio, Finland, ³Seinäjoki Central Hospital, Seinäjoki, AL, Finland

PRS13	THE COST-EFFECTIVENESS OF VARENICLINE IN SMOKING CESSATION IN DENMARK
	Poulsen PB¹, Dollerup J¹, Keiding H²
	¹Pfizer Denmark, Ballerup, Denmark, ²University of Copenhagen, Copenhagen, Denmark

PRS14	COST OF ALLERGIC RHINITIS IN PEDIATRIC PATIENTS IN MEXICO
	Del-Rio Navarro B¹, Reyes-Lopez A¹, Lemus A²
	¹"Federico Gomez" Mexican Children Hospital, Mexico City, Mexico, ²Sanofi aventis de México, Mexico City, D.F, Mexico

PRS15	ESTIMATING EXCESS COSTS OF POPULATION-BASED CASES WITH MILD COPD – RESULTS FROM THE KORA F3 STUDY
	Menn P¹, John J¹, Heinrich J², Döring A², Brüske-Hohlfeld I², Holle R¹
	¹Institute of Health Economics & Health Care Management, Helmholtz Center Munich, Neuherberg, Germany, ²Institute of Epidemiology, Helmholtz Zentrum Munich, Neuherberg, Germany

PRS16	THE HOSPITALIZATION COST OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN THE UNIVERSITY HOSPITAL OF ALEXANDROUPOLIS, GREECE
	Hatzikou M¹, Ravikalis V², Steiropoulos P³, Geitona M¹, Bouros D³
	¹University of Thessaly, Volos, Greece, ²University of Alexandroupolis, Alexandroupolis, Greece, ³University Hospital of Alexandroupolis, Alexandroupolis, Greece

PRS17	COMPARISON OF OUTPATIENT AND INPATIENT COSTS OF MODERATE AND SEVERE EXACERBATIONS OF COPD IN POLAND IN 2007
	Jahnz-Rózyk K, Targowski T, Mierzejewska MJ, From S
	Military Institute of Health Service, Warsaw, Poland

PRS18	DIFFERENCES IN TREATMENT COSTS AND RESOURCE UTILIZATION AMONG COPD PATIENTS TREATED WITH ALBUTEROL MDI OR LEVALBUTEROL MDI
	Ohsfeldt R¹, Summers KH², Lage MJ³, Brooks JM⁴, Brewster C⁵
	¹Texas A&M Health Science Center, College Station, TX, USA, ²Purdue University, West Lafayette, IN, USA, ³HealthMetrics Outcomes Research, LLC, Groton, CT, USA, ⁴USRDS Economic Special Study Center, The University of Iowa, Iowa City, IA, USA, ⁵Teva Neuroscience/Teva Specialty Pharmaceuticals, Kansas City, MO, USA
RESPIRATORY-RELATED DISORDERSPatient-Reported Outcomes Studies
PRS19	RATES OF DISCONTINUATION AMONG COMMONLY PRESCRIBED MEDICATIONS IN THE US
	Vanelli MR, Pedan A, Messier D, Hoar J, Liu N, Kiarsis K
	Adheris, Inc, Burlington, MA, USA

PRS20	SYSTEMATIC REVIEW OF FIXED-DOSE COMBINATIONS AND UNIT-OF-USE PACKAGING IN PATIENTS WITH HYPERTENSION, DYSLIPIDEMIA, AIDS, ASTHMA AND DIABETES TYPE 2
	Paladio N, Almazan C, Moharra M
	Catalan Agency for Health Technology Assessment and Research, Barcelona, Spain

PRS21	CAN ASTHMA QUALITY OF LIFE QUESTIONNAIRE (AQLQ) DATA FROM DIFFERENT COUNTRIES BE COMBINED FOR ANALYSES?
	Williams AE¹, Frith L², Gul N², Agier L³, Juniper E⁴
	¹GlaxoSmithKline R&D, Uxbridge, United Kingdom, ²GlaxoSmithKline R&D, London, United Kingdom, ³ENSAI Engineering School, Bruz, France, ⁴McMaster University, Hamilton, Ontario, Canada

PRS22	ARE THE MEASUREMENT PROPERTIES OF THE ASTHMA QUALITY OF LIFE QUESTIONNAIRE (AQLQ) CONSISTENT ACROSS LANGUAGES?
	Juniper E¹, Agier L², Williams AE³, Frith L⁴, Gul N⁴
	¹McMaster University, Hamilton, Ontario, Canada, ²ENSAI Engineering School, Bruz, France, ³GlaxoSmithKline R&D, Uxbridge, United Kingdom, ⁴GlaxoSmithKline R&D, London, United Kingdom

PRS23	IS THE EQ-5D RESPONSIVE TO RECOVERY FROM A MODERATE COPD EXACERBATION?
	Goossens L¹, Rutten-van Molken M¹, Nivens C²
	¹Erasmus MC, Rotterdam, Netherlands, ²Boehringer-Ingelheim Pharmaceuticals, Ridgefield, CT, USA

PRS24	QUALITY OF LIFE RESULTS USING THE EUROQOL QUESTIONNAIRES AND DIRECT MEDICAL COSTS IN ASTHMATIC PATIENTS. CHAS STUDY
	Tafalla M, Nuevo J, Cordero L, Hernandez R
	AstraZeneca, Madrid, Spain

PRS25	THE PUBLIC'S WILLINGNESS TO PAY FOR A QALY IN THAILAND
	Thavorncharoensap M, Teerawattananon Y, Natanant S, Kulpeng W
	Health Intervention and Technology Assessment Program (HITAP), Nontaburi, Thailand

PRS26	THE EXACT-PRO INITIATIVE: DEVELOPMENT AND VALIDATION OF A SINGLE PATIENT-REPORTED OUTCOME MEASURE FOR EVALUATING EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
	Leidy NK, Wilcox TK, Roberts L, Winnette RM, Murray L
	United BioSource Corporation, Bethesda, MD, USA

PRS27	INTERPRETING SCORES ON THREE PATIENT-REPORTED OUTCOME MEASURES FOR ASTHMA
	Meads DM¹, Twiss J¹, McKenna SP¹, Revicki D², Pokrzywinski R³, Gale R⁴
	¹Galen Research, Manchester, United Kingdom, ²United BioSource Corporation, Bethesda, MD, USA, ³United Biosource Corporation, Pittsburgh, PA, USA, ⁴Novartis AG, Horsham, United Kingdom

PRS28	HAS ASTHMA CONTROL IMPROVED SINCE AIRE? RESULTS OF A SURVEY IN 5 EUROPEAN COUNTRIES
	Gueron B¹, Freedman D², Annunziata K², Poterre M¹
	¹GSK, Marly le Roi, France, ²Consumer Health Sciences, Princeton, NJ, USA

PRS29	SOCIOECONOMIC ANALYSIS OF SMOKER'S PROFILE WHO INTENDS TO QUIT
	Ramón JM¹, Bruguera E², Sanz de Burgoa V³, Ramírez E⁴
	¹Hospital de Bellvitge, Barcelona, Spain, ²Hospital Vall d'Hebron, Barcelona, Spain, ³Laboratorios Pfizer, Alcobendas, Madrid, Spain, ⁴Infociencia S.L, Barcelona, Spain

PRS30	HOW CONGRUENT ARE PATIENT AND CLINICIAN MODELS OF ASTHMA CONTROL? – PRELIMINARY FINDINGS FROM A QUALITATIVE STUDY
	Ruedell K¹, Bonner N², Arbuckle R², Abetz L³, Hareendran A⁴, Gilbert C⁴
	¹Pfizer Ltd, Sandwich, United Kingdom, ²Mapi Values Ltd, Bollington, United Kingdom, ³Mapi Values, Bollington, United Kingdom, ⁴Pfizer, Ltd, Sandwich, United Kingdom

PRS31	A SURVEY OF THE BURDEN OF ALLERGIC RHINITIS IN EUROPE
	Gueron B¹, Canonica GW², Bousquet J³, Mullol J⁴, Scadding G⁵, Virchow JC⁶
	¹GSK, Marly le Roi, France, ²University of Genova, Genova, Liguria, Italy, ³INSERM, Montpellier, MT, France, ⁴Institut D'investigacions Biomediques August Pi I Sunyer, Barcelona, Spain, ⁵Royal National Throat, Nose and Ear Hospital, London, United Kingdom, ⁶Universitatsklinik Rostock, Rostock, Germany

PRS32	SYMPTOMS AND IMPACT OF SYMPTOMS AS REPORTED BY ASTHMA PATIENTS
	Williams A¹, Jacques L¹, Rofail D², Heelis R²
	¹GlaxoSmithKline R&D, Uxbridge, United Kingdom, ²Mapi Values, Bollington, Cheshire, United Kingdom

PRS33	FACTORS AFFECTING QUALITY OF LIFE OF ASTHMATIC AND COPD PATIENTS
	Meszaros A, Orosz M, Mesko A
	Semmelweis University, Budapest, Hungary

PRS34	QUALITY OF LIFE DURING ACUTE EXACERBATIONS OF COPD: COMPARING EQ-5D, SF-12 AND SGRQ
	Menn P¹, Weber N², Häußinger K², Holle R¹
	¹Institute of Health Economics & Health Care Management, Helmholtz Center Munich, Neuherberg, Germany, ²Asklepios Fachkliniken, Gauting, Germany

PRS35	CHALLENGING ASTHMA MANAGEMENT WITH THE USE OF LABA/ICS COMBINATION VIA A TURBUHALER DEVICE, BOTH FOR MAINTENANCE AS WELL AS RELIEF, AND IT'S INFLUENCE ON ASTHMA CONTROL AND PATIENTS' WELL-BEING IN GREECE
	Rasidakis A¹, Kostagiolas L², Daskos G²
	¹Metropolitan Hospital, Athens, Greece, ²AstraZeneca SA, Athens, Greece

PRS36	WILLINGNESS TO PAY FOR CAREGIVERS OF PEDIATRIC ASTHMATIC PATIENTS IN KOREA
	Park D¹, Ko S²
	¹Seoul National University, Seoul, South Korea, ²Pfizer Korea, Seoul, South Korea
RESPIRATORY-RELATED DISORDERSHealth Care Use & Policy Studies
PRS37	RACIAL DISPARITIES IN UTILIZATION OF ASTHMA CONTROLLER DRUG THERAPY
	Vaidya V¹, Hufstader MA²
	¹University of Tennessee, Memphis, TN, USA, ²University of Tennessee Health Science Center, Memphis, TN, USA

PRS38	DEVELOPMENT OF EXPLICIT APPROPRIATENESS CRITERIA FOR THE INDICATION OF ADMISSION FROM PATIENTS WITH ACUTE COPD EXACERBATION
	Quintana JM¹, Escobar A², Esteban C³, Aguirre U³, Garcia S³, Gonzalez N³
	¹Hospital de Galdakao-Usansolo, Galdakao, Spain, ²Hospital de Basurto, Bilbao, Spain, ³Hospital Galdakao-Usansolo, Galdakao, Vizcaya, Spain

PRS39	GIVING-UP SMOKING: PREDICTIVE FACTORS OF SMOKING CESSATION AND ATTEMPTS TO STOP IN A FRENCH COHORT
	Thomas D
	Cardiology Institut, Paris cedex 13, Paris, France

PRS40	DECISION-MAKING IN HEALTH CARE USING COST-EFFECTIVENESS EVIDENCE - SMOKING CESSATION COMPARED TO TREATMENT OF SMOKING-RELATED DISEASES
	Poulsen PB¹, Dollerup J¹, Randskov HJ¹, Pedersen KM²
	¹Pfizer Denmark, Ballerup, Denmark, ²University of Southern Denmark, Odense, Denmark
RESPIRATORY-RELATED DISORDERSConceptual Papers & Research on Methods
PRS41	USE OF AN ELECTRONIC DIARY IN 55 COUNTRIES: WHAT ARE THE CHALLENGES?
	Muller S¹, Kaschinski D²
	¹Mapi Research Institute, Lyon, France, ²Boehringer Ingelheim International GMBH, Ingelheim/Rhein, Germany

PRS42	SMOKING-CESSATION ACROSS BORDERS: TRANSFERABILITY OF COST-EFFECTIVENESS RESULTS
	Vemer P, Rutten-van Molken M
	Erasmus MC, Rotterdam, The Netherlands